

# MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") should be read in conjunction with the condensed interim consolidated financial statements of Helix BioPharma Corp. (the "Company" or "Helix") for the three and nine-month periods ended April 30, 2020 and 2019 and the accompanying notes thereto. This MD&A is based on financial statements which have been prepared in accordance with International Financial Reporting Standards ("IFRS"). All amounts are depicted in Canadian currency unless otherwise noted.

Additional information relating to the Company can be found in the Company's Annual Information Form, which is available on SEDAR at [www.sedar.com](http://www.sedar.com).

## FORWARD-LOOKING INFORMATION

This MD&A contains forward-looking information (collectively, "forward-looking information") within the meaning of applicable Canadian securities laws. Forward-looking information means disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes financial projections and estimates; statements regarding plans, goals, objectives, intentions and expectations with respect to the Company's future business, operations, research and development, including the focus of the Company's primary drug product candidate L-DOS47 and other information relating to future periods. Forward-looking information includes, without limitation, statements concerning (i) the Company's ability to continue to operate on a going concern basis being dependent mainly on obtaining additional financing; (ii) the Company's growth and future prospects being dependent mainly on the success of L-DOS47; (iii) the Company's priority continuing to be L-DOS47; (iv) the Company's development programs, including but not limited to, extension of the current drug candidate(s) to other indications and the identification and development of further tumour-targeting antibodies for DOS47; (v) the nature, design and anticipated timeline for completion of enrollment and other matters relating to the Company's ongoing clinical study programs such as the LDOS003 study combining L-DOS47 with Vinorelbine/Cisplatin ("VIN/CIS") for advanced stage lung cancer patients and the recently approved Investigational New Drug ("IND") Phase Ib/II combination study combination with doxorubicin for previously treated advanced pancreatic cancer patients by U.S Food and Drug Administration ("FDA"); (vi) seeking strategic partner support and therapeutic market opportunities; (vii) the Company's advancement in the area of cell based therapy via its subsidiary Helix Immuno-Oncology S.A. ("HIO") (viii) future expenditures, insufficiency of the Company's current cash resources and the need for financing and the Company's possible response for such matters; (ix) future financing requirements, the seeking of additional funding (including the possible receipt of grants) and anticipated future operating losses; (x) changes in the application of accounting standards and interpretations; and (xi) industry performance, competition (including potential developments relating to immunotherapies and the Company's possible response to such developments), prospects, and general prevailing business and economic conditions. Forward-looking information can further be identified by the use of forward-looking terminology such as "expects", "plans", "designed to", "potential", "believe", "intended", "continues", "opportunities", "anticipated", "2019", "2020", "2021", "2022", "next", "ongoing", "seek", "objective", "estimate", "future", or the negative thereof or any other variations thereon or comparable terminology referring to future events or results, or that events or conditions "will", "may", "could", "would", or "should" occur or be achieved, or comparable terminology referring to future events or results.

Forward-looking information includes statements about the future and are inherently uncertain and are necessarily based upon a number of estimates and assumptions that are also uncertain. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Forward-looking information, including financial outlooks, are intended to provide information about management's current plans and expectations regarding future operations, including without limitation, future financing requirements, and may not be appropriate for other purposes. The Company's actual results could differ materially from those anticipated in the forward-looking information contained in this MD&A as a result of numerous known and unknown risks and uncertainties, including, but not limited to:

- the Company's need for additional capital which may not be available in a timely manner or at all (whether from additional issuances of the Company's securities, grant applications or otherwise) and which, if not obtained, will have a material adverse impact on the Company and its ability to continue as a going concern;
- the risk that the Company may have to suspend or terminate one or more of its clinical trials for lack of funding, as the Company does not have sufficient funds to complete them and will need to raise additional funding, which is not assured;
- uncertainty as to whether the Company's drug product candidate(s), especially L-DOS47, will be successfully developed and marketed;
- developments in immunotherapies may result in significant changes in the treatment of cancer and may result in a reduction, which may be significant, in the potential patient population and/or treatment protocols available to chemotherapies and other treatments currently in development, such as the Company's primary drug product L-DOS47;

- the possibility of dilution to current shareholders from future equity financings;
- the impact of the ongoing volatility in the economic environment which has negatively affected the availability and terms of debt and equity financings and may have a negative effect on the Company's ability to raise further financing and its research and development initiatives;
- risk relating to the difficulty in enrolling patients in clinical trials which may result in delays or cancellation of clinical trials;
- intellectual property risks, including the possibility that patent applications may not result in issued patents, that issued patents may be circumvented or challenged and ultimately struck down, that any expiry of an issued patent, may negatively impact the further development or commercialization of the underlying technology, and that the Company may not be able to protect its trade secrets or other confidential proprietary information;
- research and development risks, including without limitation, the fact that the Company's drug product candidate(s) are complex compounds and the Company faces difficult challenges in connection with the manufacture of clinical batches, and the risk of obtaining negative findings or factors that may become apparent during the course of research or development, any of which may result in the delay or discontinuation of the research or development projects;
- partnership/strategic alliance risks and the need to secure new strategic relationships, which are both not assured;
- the Company's dependence on third parties, including without limitation, contract research organizations, contract manufacturing organizations, clinical trial consultants, collaborative research consultants, regulatory affairs advisors, and others, whose performance and interdependence can critically affect the Company's performance and the achievement of its milestones;
- the Company's dependence on assurances from third parties regarding licensing of proprietary technology owned by others, including the Company's dependence on its license of the L-DOS47 antibody;
- the need for future clinical trials, the occurrence and success of which cannot be assured, and the fact that results seen in earlier clinical trials may not be repeated in later trials;
- manufacturing risks, the need to manufacture to regulatory standards, uncertainty whether the manufacturing process for the Company's drug candidates can be further scaled-up successfully or at all and the risk that clinical batches of the Company's drug candidate may not be able to be produced in a timely manner or at all, which would have a negative effect on the timing and/or occurrence of planned clinical trials and the potential commercialization of the drug candidates;
- the possibility that ongoing drug product stability assay tests may fail, resulting in stoppage and delay of clinical study activity until such time that approved drug product is available and approved for use;
- uncertainty as to the size and existence of a market opportunity for, and market acceptance of the Company's drug product candidate(s) including as a result of possible changes in the market for the Company's drug candidates resulting from development in immunotherapies or other future cancer treatments;
- uncertainty as to the availability of raw materials that the Company utilizes to manufacture its products, and in particular, Good Manufacturing Practice ("GMP") grade materials, on acceptable terms or at all, and that the Company may not be able to timely obtain alternative suppliers upon commercially viable terms or at all, which could have a material adverse effect on the further development and commercialization of any or all of the Company's drug product candidate(s);
- the risk that either the Polish National Centre for Research and Development ("PNCRD") or the Company will terminate the grant funding agreement &/or that the PNCRD will not extend any extensions to the already set milestones for reasons that may result in the PNCRD requesting from the Company that any received financial support be paid in full within fourteen days of the day notice is served, with interest, as per the agreement;
- product liability and insurance risks;
- the risk of lawsuits and other legal proceedings against the Company;
- the effect of competition, especially from the new immunotherapy treatments for non-small cell lung cancer ("NSCLC");
- the risk of unknown side effects arising from the development, manufacture or use of the Company's products;
- uncertainty as to the Company's ability to maintain product liability insurance required by third parties and the risk of the corresponding agreement being terminated;
- the risk of misconduct on the part of employees and consultants, including non-compliance with regulatory standards and requirements;
- the need to attract and retain key personnel and reliance on key personnel;
- that the Company has no sales, marketing and distribution experience;
- government regulation, including drug price regulation, and the need for regulatory approvals for both the development and profitable commercialization of products, which are not assured;
- risks associated with the fact that the FDA and any other regulatory agency that the Company has consulted are not bound by their scientific advice, nor are any approvals given by one regulatory body binding on another;
- rapid technological change and competition from pharmaceutical companies, biotechnology companies and universities, which may make the Company's technology or products obsolete or uncompetitive;
- risks associated with claims, or potential claims, of infringement of third-party intellectual property and other proprietary rights;

- the risk of unanticipated expenses;
- the impact on the Company's finances resulting from shifts in foreign exchange rates, credit risk and interest rate risk,
- risks relating to changes in the Company's tax rates;
- risk relating to a failure to maintain an effective system of internal controls;
- risks relating to the requirements of remaining a public company;
- risk associated with the Novel Coronavirus pandemic;

and other risk factors that are discussed above and elsewhere in this MD&A or identified in the Company's other public filings under the Company's profile on SEDAR at [www.sedar.com](http://www.sedar.com) (together the "Helix Risk Factors"), any of which could cause actual results to vary materially from current results or the Company's anticipated future results. Certain material factors, estimates or assumptions have been applied in making forward-looking information in this MD&A, including, but not limited to, the safety and efficacy of the Company's drug product candidate(s); the Company's cost and timing in connection with the various clinical studies the Company is currently conducting or plans to conduct; that additional and sufficient financing will be obtained in a timely manner or at all to allow the Company to continue operations; the timely provision of services and supplies or other performance of contracts by third parties; future costs; the absence of any material changes in business strategy or plans, the timely receipt of required regulatory approvals, strategic partner support; and that the Helix Risk Factors will not cause the Company's actual results or events to differ materially from the forward-looking information.

For all of the reasons set forth above, which do not represent an exhaustive list of factors that may affect the forward-looking information, investors should not place undue reliance on forward looking information. The forward-looking information is based on the beliefs, assumptions, opinions and expectations of the Company's management at the time they are made, and the Company does not assume any obligation to update any forward-looking information should those beliefs, assumptions, opinions or expectations, or other circumstances change, except as required by law.

Data relevant to estimated market sizes in connection with Company's lead products under development are presented in this MD&A. These data have been obtained from a variety of published resources, including published scientific literature, websites and information generally available through publicized means. The Company attempts to source reference data from multiple sources whenever possible for confirmatory purposes. Although the Company believes the data is reliable, the Company has not independently verified the accuracy and completeness of this data.

## OVERVIEW

Helix BioPharma Corp. is a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on our proprietary technological platform DOS47.

Helix is pioneering the development of a platform technology targeting the tumour microenvironment. Helix's technology is designed to reduce tumour acidity, an escape mechanism which cancer cells utilize to evade the anti-tumour immune response. Tumour acidity has been shown to correlate with resistance to anti-cancer treatment and poor prognosis for cancer patients.

To date, the Company's proprietary technology platform, DOS47, has yielded two new drug product candidates, being L-DOS47 and V-DOS47.

L-DOS47 is currently under clinical study for the treatment of non-small cell lung cancer ("NSCLC") and previously treated advanced pancreatic cancer. The Company completed extensive preclinical testing and manufacturing development of L-DOS47, following which the Company obtained regulatory approvals to conduct a Phase I/II NSCLC monotherapy clinical study in Poland, a Phase I NSCLC combination study with pemetrexed and carboplatin in the United States, and a Phase II NSCLC combination study with vinorelbine and cisplatin in Ukraine and Poland. In August 2019, the Company also received approval to conduct a Phase Ib/II combination study utilizing L-DOS47 with doxorubicin in patients with previously treated advanced pancreatic cancer in the United States.

V-DOS47 drug candidate uses the Company's proprietary DOS47 technology conjugated to anti-VEGFR2 antibody targeting a wide range of cancers. V-DOS47 was licensed to the Company's then wholly owned subsidiary in Poland, Helix Immuno-Oncology S.A. ("HIO") for which HIO would be responsible for all pre-clinical and clinical development with funding provided predominately from the Polish National Centre for Research and Development ("PNCRD"). On January 30, 2020, HIO conveyed to the PNCRD that it wished to terminate the grant funding program for V-DOS47.

In NSCLC, L-DOS47 is shown to be safe and well tolerated as a monotherapy pursuant to the Company's LDOS002 study ("LDOS002"). L-DOS47 is also shown to be safe and well tolerated when used in combination with pemetrexed and carboplatin pursuant to the Company's LDOS001 study ("LDOS001"). LDOS001 was conducted in University Hospital's Case Medical Center in Cleveland, Ohio, Penn State's Cancer Institute in Hershey, Pennsylvania and at the University of Texas MD Anderson Cancer Center in Houston, Texas. As reported at the May 2020 conference of the American Society of Clinical Oncology, an objective response rate of 41.7% based on tumour burden and a clinical benefit rate of 75% inclusive of stable diseases were observed in the LDOS001 study. The Company believes the data supports the continuing development of L-DOS47 for NSCLC. As of the

date of this short form prospectus, the Company is contemplating a new study in NSCLC using L-DOS47 in combination with immunotherapy. The Company is also seeking a partner to further its Phase II study of L-DOS47 in combination with vinorelbine and cisplatin ("LDOS003").

In December 2019, the Company announced the start of enrollment and screening for its Phase Ib/II clinical development program for previously treated patients with advanced pancreatic cancer. The study center is located in Scottsdale, Arizona at the Scottsdale Hospital ("dba HonorHealth"). The Company is forecasting enrollment in the Phase Ib portion of the study to be completed by the end of the 2020 calendar year, pending safety outcomes and the impact of the COVID-19 pandemic. Please see "Our results of operations may be negatively impacted by the COVID-19 outbreak" under the heading "Risk Factors".

In 2017, the Company entered into a scientific research collaboration agreement with the Moffitt Cancer Center ("Moffitt") in Tampa, Florida, to perform basic research studies to further investigate the pharmacodynamics of L-DOS47 and to determine the potential benefits of combining L-DOS47 with immune checkpoint inhibitors. The Company's collaboration with Moffitt continues to expand with the recent announcement of a new animal model research project involving the use of L-DOS47 in combination with immunotherapy in pancreatic cancer. Pancreatic cancer is known to be a disease that is resistant to immunotherapy treatment and shown in animal models to be highly acidic. The Company believes the ability of L-DOS47 to modulate tumour acidity may be key to enable immunotherapy treatment for pancreatic cancer. This new research collaboration project will also build on data already obtained from imaging techniques performed by Moffitt that demonstrated the ability of L-DOS47 to affect tumour acidity. Translation of this technique into the clinic may help stratify patients for L-DOS47 and potentially identify patients who may be resistant to certain therapies due to tumour acidity.

In addition to DOS47, the Company has also developed antibodies that may be suitable for novel chimeric antigen receptor T-Cell therapeutic ("CAR-T") for solid tumours. In March 2018, the Company announced a scientific research collaboration with ProMab Biotechnologies Inc. ("ProMab") to co-develop novel antibody and CAR-T's for various hematological malignancies and solid tumours. The first scientific research collaboration between the two parties involves a co-development program for a cell-based therapy in multiple myeloma. The aim was for both parties to perform various tasks with the objective of filing an investigational new drug application ("IND") for testing in humans by early 2019. The Company's working capital deficiency through August of 2019 has pushed out the originally planned timeline for IND filing. Under the scientific research collaboration agreement with ProMab, the Company retained the rights for the multiple myeloma CAR-T in Canada and Europe and then sublicensed the European rights to its then wholly-owned subsidiary, HIO, to further develop and commercialize these technologies in return for future milestone payments and royalty fees. The Company will provide certain technical and funding support in the early preclinical stages of the multiple myeloma scientific research collaboration program with ProMab. Under the sublicense agreement between the Company and HIO, HIO was expected to fully support the clinical development of cell therapy products and has recently applied for government grant assistance in Poland.

In December 2016, the Company signed an exclusive out-license agreement with Xisle Pharma Ventures Trust ("Xisle") for the Company's late-stage, Biphasix™ technology platform, including the lead product candidate, interferon alpha. Under the terms of the agreement, Xisle paid an up-front fee and agreed to pay subsequent milestone payments and royalties to the Company as Xisle advances the technology. As part of the agreement, the Company retained marketing rights for Belarus, Bulgaria, the Czech Republic, former Eastern Germany, Hungary, Moldova, Poland, Romania, Russia, Slovakia and Ukraine and non-exclusive rights for co-promotion in Canada. The Company subsequently assigned the foregoing marketing rights to its then wholly-owned subsidiary in Poland, HIO pursuant to an agreement between the Company and HIO with the agreement being subject to the restrictions and limitations associated with the out-license agreement signed between the Company and Xisle.

On June 25, 2020, the Company announced that it had approved, in its capacity as a shareholder of HIO, a direct investment in HIO by an investor which resulted in the Company's ownership in HIO being reduced to approximately 42.5% on July 8, 2020. The direct investment in HIO permitted HIO to apply for a new government grant for the development of the multiple myeloma CAR-T program in Poland. The Company also announced the receipt of a non-binding offer from CAIAC Fund Management AG ("CAIAC") to purchase the Company's remaining shares in HIO. The transaction is expected to close on or about August 31, 2020 subject to the satisfaction of certain conditions, including, but not limited to, the negotiation of binding documentation, the receipt of a minimum of PLN7,300,000 by CAIAC pursuant to a financing, and the receipt of all required regulatory approvals.

On June 25, 2020, the Company also announced the cancellation of intercompany debt in the total aggregate amount of approximately \$2,700,000 ("Debt Cancellation") owed to the Company by HIO. As part of the Debt Cancellation, both the V-DOS47 and Biphasix™ agreements between the Company and HIO were terminated with immediate effect.

The Company has an extensive patent portfolio that includes company owned and licensed patents and pending applications, including, but not limited to, the use of DOS47 as immunoconjugate for cancer treatment. The Company also has licenses with the National Research Council of Canada ("NRC") that cover the use of antibodies for L-DOS47, other DOS47 candidates and cellular therapy products. Issued patents have coverage in all major pharmaceutical markets including North America, Europe, and Asia.

The Company currently believes that its growth and future prospects are mainly dependent on the success of its DOS47 drug product candidates.

## **RESEARCH AND DEVELOPMENT ACTIVITIES**

### **Background**

The immune system utilizes two strategies in attacking different types of pathogens. The humoral immune system uses antibodies as its main weapon. Antibodies are proteins that bind to extracellular foreign invaders, such as bacteria, and lead to their destruction. The cellular immune system utilizes specialized immune cells, called T-cells to identify and bind to abnormal cells and subsequently destroy them.

Cancer cells have adopted and developed several strategies for evading the immune system. In some cases, proteins are expressed on the surface of tumour cells that “turn off” attacking T-cells. By using antibodies to block these interactions (such as anti-PD1), T-cells are reactivated to kill the tumours. Although anti-PD1 and anti-PDL1 therapies (checkpoint inhibitors) have improved outcomes for patients, there are many that do not respond to these treatments. One possible explanation suggests that the unique metabolism of cancer cells creates an acidic tumour microenvironment and this acidity has the effect of interfering with T-cell function. The Company believes it has developed a novel system to raise pH at the tumour site, thus breaking the physiologic barrier that acts to defend against tumour-killing T-cells.

### ***Alkalization using Urease***

Urease is an enzyme that catalyzes the hydrolysis of urea into carbon dioxide and ammonia ( $(\text{NH}_2)_2\text{CO} + \text{H}_2\text{O} \rightarrow \text{CO}_2 + 2\text{NH}_3$ ). The Company has conjugated urease to an antibody that specifically targets lung cancer cells, thus delivering the urease directly to the site of the tumour. L-DOS47, the Company’s first drug product candidate, has recently completed a Phase I/II monotherapy trial in Poland. It is currently in a Phase I combination trial with carboplatin and pemetrexed in the United States and a Phase II combination trial with vinorelbine and cisplatin in Ukraine and Poland. By delivering urease to the tumour site, the company expects the pH of the tumour microenvironment to increase and activity of tumour-killing T-cells to be enhanced. The Company believes the urease system can be used with any tumour specific antibody as a general method for modifying the tumour microenvironment, and as such, could be combined with any of the current checkpoint inhibitor products to improve patient outcomes.

### ***CAR-T Cells***

To date, success in Adoptive Cell Transfer (“ACT”) with engineered T-cells such as Chimeric Antigen Receptor T-cells (“CAR-T”) has occurred mainly in the area of hematological malignancies. As of the end of 2016, 220 CAR T cell trials were documented of which approximately 188 are ongoing including nine long-term follow-up studies. Of the current trials, 133 target hematological malignancies and 78 solid tumors (Hartman et. al, EMBO Mol Med (2017) 9: 1183–1197). Most clinical trials have used autologous, unselected peripheral blood mononuclear cells (“PBMC”) as the starting material and IL-2 for stimulation resulting in a CAR-T cell product consisting of CD4 and CD8 T cells with an activated effector T-cell phenotype. In five trials, more than 85% of treated patients reached complete response (“CR”) as best clinical outcome (Hartman et. al, EMBO Mol Med (2017) 9: 1183–1197).

While CAR-T cell therapy has shown impressive clinical benefit, it is sometimes associated with a variety of toxicities that can be life-threatening. Several death cases have been reported, especially in the last year. These were due to neurotoxicity caused by cerebral edemas in the CD19-CAR trials sponsored by Juno Therapeutics. Whether neurological toxicities are solely restricted to CD19-specific CAR-T cells or generally associated with CAR-T cell therapy remains to be elucidated (Hartman et. al, EMBO Mol Med (2017) 9: 1183–1197).

A direct connection to another frequent side effect, the cytokine-release syndrome (“CRS”), also appears likely. CRS has so far been the most frequently observed adverse drug reaction. On-target, off-tumor recognition has become a relevant concern, since many targeted tumor antigens are also expressed on normal tissue (Hartman et. al, EMBO Mol Med (2017) 9: 1183–1197).

Solid tumours have created challenges and as such, it is hypothesized that the failure of CAR-T therapies to date may be the result of the acidic tumour microenvironment surrounding the cancer cell that inhibits CAR T-cell activity. The Company believes it is well positioned to use its proprietary urease-antibody technology to alkalinize the tumour microenvironment and improve the ability of CAR-T cells to destroy solid tumours.

### ***Check Point Inhibitors***

Dr. Robert J. Gillies of the Moffitt Cancer Center in Tampa Florida demonstrated some interesting results when treating acidic tumours in animal models. Dr. Gillies demonstrated that in alkalinized tumour cells, the activity of antibodies that target PD-L1, is enhanced. This would indicate that tumour acidosis may protect tumours from immune check-point inhibitors. Since tumour acidosis is experimentally shown to occur in cancers such as breast, colon, lung and pancreas, the Company believes methodologies that can alkalinize the tumour microenvironment, such as the Company’s proprietary DOS47 platform technology, may work beneficially with check-point inhibitors.

## **DOS47 – A broad anti-cancer therapeutic platform**

DOS47 is based upon a naturally occurring enzyme isolated from the jack-bean plant called urease that breaks down a natural substance found in the body, urea, into metabolites that include ammonia and hydroxyl ions. By doing so at the site of cancerous tissues in the body, the Company believes DOS47 can modify the micro environmental conditions of cancerous cells in a manner that leads to apoptosis.

DOS47 stimulates an increase in the pH of the microenvironment surrounding the cancerous cells, effectively reversing the acidic extra-cellular conditions that are believed to act to defend the tumour. This acidic environment can also reduce or negate the effectiveness of some commonly used anti-neoplastic agents. The local production of ammonia at the site of cancerous tissues is thought to readily diffuse into the cancer cells to exert a potent cytotoxic effect by interfering with their critical metabolic functions. Enzymatic action of urease at the site of cancerous cells is potentially repetitive and sustainable due to the plentiful supply of urea.

The Company is pursuing the development of DOS47 as an adjunct therapy in combination with certain chemotherapeutics, immunotherapies and/or radiation regimens, with a view to maximizing the DOS47 commercial potential.

DOS47 candidates are produced by conjugating urease with a targeting antibody or antibody fragment that can specifically direct the urease to the surface of a cancer cell. Once docked to the cell, the urease produces ammonia enzymatically through the conversion of urea found throughout the body. These conjugates of antibodies to urease are called DOS47 candidates. By selecting antibodies that are selective to different tumour cell surface receptors, the Company believes that DOS47 candidates can be used in several types of solid tumours.

### ***L-DOS47***

L-DOS47 is the Company's first targeted therapeutic immune-conjugate under development based on the DOS47 technology. L-DOS47 is an antibody protein conjugate where the urease component enzymatically converts naturally occurring urea to ammonia. The L-DOS47 drug molecule includes a highly specialized camelid-derived single domain antibody, designed to identify a unique CEACAM6 antigenic site associated with NSCLC cells. By delivering the conjugate in a targeted manner, the Company believes L-DOS47 stimulates an increase in the pH of the microenvironment surrounding the NSCLC cells, reversing the acidic extra-cellular conditions that are shown to be favourable for cancer cell survival.

In 2005, the Company entered into a worldwide exclusive license with the National Research Council of Canada ("NRC"), through which it obtained the rights to combine this highly specialized camelid-derived single domain antibody with Helix's DOS47 technology. As a result, the Company has certain royalty and milestone payment obligations pursuant to the license agreement. The license agreement with the NRC has been filed under the Company's profile on SEDAR at [www.sedar.com](http://www.sedar.com). The NRC filed patent applications in respect of the antibody in Canada, the United States and other countries. On March 2, 2011, the NRC was issued a U.S. patent in respect of the antibody.

In addition to being a key for cancer progression by promoting invasiveness and metastatic behaviors of cancer cells, the acidic tumour microenvironment protects cancer cells from immunotherapy by suppressing the proliferation and cytotoxic activities of local immune cells. A series of experiments were performed in which L-DOS47 was used to neutralize acidic tissue culture media and the effects on tumor and immune cells in vitro were studied. L-DOS47 treatment reduced PD-L1 expression on the MDA-MB-231 breast cancer cell line and increased IL-2 production from the Jurkat human T cell line. In addition, L-DOS47 reduced PD-1 expression on primary human CD8+ T cells, and increased IL-2 and IFN $\gamma$  production by primary human CD8+ T cells, suggesting that L-DOS47 treatment may improve anti-tumor immune responses.

In 2017, the Company entered into the first scientific research collaboration agreement with the Moffitt Cancer Center ("**Moffitt**") in Tampa, Florida, to perform basic research studies to further investigate the pharmacodynamics of L-DOS47 and to determine the potential benefits of combining L-DOS47 with immune checkpoint inhibitors. Under the research plan Moffitt performed in vitro and in vivo research studies on the pharmacodynamics of L-DOS47 and its effect when combined with check-point blockage agents using their unique tumor models. A second scientific research collaboration agreement was entered into by both parties to extract radiomics data using Moffitt's proprietary HealthMyne platform from CT scans of late stage lung cancer patients treated with L-DOS47. The methodology has been incorporated in the Company's LDOS006 Phase Ib/II clinical study on

The Company's collaboration with Moffitt continues to expand with the recent announcement of a third scientific research collaboration agreement animal model research project involving the use of L-DOS47 in combination with immunotherapy in pancreatic cancer.

### ***V-DOS47***

V-DOS47 is an antibody DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor (VEGFR2). V-DOS47 is the second immuno-oncology drug candidate derived from the Company's DOS47 technology platform.

In January 2016, the Company granted a world-wide exclusive license for V-DOS47 to HIO in Poland.

On July 21, 2016, the Company announced that a grant funding agreement was entered into by the Company's subsidiary in Poland with the PNCRD, whereby certain expenditures made commencing on March 1, 2016 would be subsidized. Based on the grant funding agreement, certain expenditures made commencing on March 1, 2016 are eligible for reimbursement with the final reimbursement submission to be made no later than September 30, 2021. The agreement may be terminated by either party upon one month's written notice and in certain cases of termination, the Company's Polish subsidiary may be obligated to return the received financial support in full within fourteen days of the day notice is served, with interest.

The Company had previously developed four V-DOS47 research candidates and conducted *in vitro* feasibility studies to establish the potential clinical applications for these molecules. Under the program approved by the PNCRD, HIO was to leverage this know-how and develop a V-DOS47 clinical drug product candidate while the Company assisted HIO by sharing its extensive knowledge in GMP manufacturing, preclinical research and clinical experiences. HIO would also collaborate with several Polish institutes through the grant to complete the development of the first V-DOS47 clinical drug product candidate. The actual duration of the development process depended on the successful completion of preclinical research favorable for clinical testing and establishment of cGMP manufacturing processes. The Company's Polish subsidiary recently advised the PNCRD that it wished to terminate the grant funding arrangement. To date the Polish subsidiary under the grant funding agreement received approximately \$1,448,000. The Company does not believe it will be required to reimburse any amount.

As part of the debt cancellation agreements, announced by the Company on June 25, 2020, the Company and HIO have agreed to terminate both the V-DOS47 license agreement. As a result, all transferred assets related to V-DOS47 have been automatically reassigned and transferred from HIO back to the Company without any formality.

As a result, the Company will now assess what next steps to take with the V-DOS47 antibody.

### ***CAR-T for solid tumours and hematological malignancies***

#### *CEACAM6 specific CARs*

Expression of CEACAM6 protein has been reported in a variety of normal human tissues including granulocytes. However, its expression is elevated in many types of solid tumours such as breast, pancreatic, ovarian, lung and colon. CEACAM6 is envisaged as a biomarker and potential therapy target for pancreatic ductal adenocarcinoma and pancreatic intraepithelial neoplasia (Duxbury et al., 2004a, 2004c, 2004d). Recently CEACAM6 is suggested to be check point molecule in multiple myeloma.

The Company believes CEACAM6 specific CAR immune cells may have broad applications in a number of cancer types. The Company is working on two camelid single domain antibodies that target CEACAM6.

2A3 is a camelid single domain antibody isolated from a whole cancer cell immunized llama library. The antibody binds specifically to the CEACAM6 antigen with high affinity and inhibits the proliferation of CEACAM6-expressing cancer cells *in vitro*. The efficacy of CEACAM6-CAR-T cells in xenograft model was examined *in vivo*. The results strongly support that CEACAM6-CAR-T cells can be used as an effective immunotherapy agent against CEACAM6-expressing cancers, and that camelid single domain antibodies can be easily adopted for CAR-T type therapies.

#### *Vascular epithelial growth factor receptor 2 (VEGFR2) CARs*

Most solid tumours and some hematologic malignancies are characterized by an angiogenic phenotype that is an absolute requirement for tumour survival, progression, and metastasis. Therapeutic approaches targeting molecules involved in tumour angiogenesis can inhibit tumour growth. Proliferating endothelial cells in the vessels within solid tumours aberrantly express high levels of angiogenic growth factors, receptors, and adhesion molecules that are absent or barely detectable in established blood vessels, which are normally quiescent. Among these, VEGF and its receptors appear to be the dominant regulators of angiogenesis responsible for the vascularization of normal and neoplastic tissues. Overexpression of VEGF and its receptors is associated with tumour angiogenesis, survival, invasion, metastasis, recurrence, and prognosis in human cancers. VEGF stimulates angiogenesis mainly through VEGFR-2 (also known as Flk1 in mice and KDR in humans), a tyrosine kinase receptor that is overexpressed in tumour endothelial cells and on some tumour cells. Pharmacologic approaches to inhibit VEGF, using monoclonal antibodies or small molecules, are of value in cancer treatment, though the cytostatic rather than cytotoxic nature of these interventions and the redundancy of angiogenic pathways have limited the curative potential of these treatments. The Company believes VEGFR2 specific CAR immune cells may have broad applications in a number of cancer types. Helix is working on two camelid single domain antibodies that target VEGFR2.

The Company is also leveraging its know-how in manipulating the tumour microenvironment, and its expertise in developing unique single domain antibody therapeutics to develop CAR-T novel cell-based treatments. Helix intends to develop CARs for ACT for solid and hematological malignancies. The Company has selected CEACAM6 and VEGFR2 specific CARs for solid tumour. For hematological malignancies the Company has selected CD19, CD22 and BCMA as potential targets.

## *ProMab Biotechnologies Inc. ("ProMab")*

In March 2018 the Company entered into a collaboration agreement with ProMab to develop novel antibody and chimeric antigen receptor T-cell therapy ("CAR-T") that target BCMA to treat multiple myeloma. In this collaboration, the Company retains commercial rights for this CAR-T in Canada and Europe. The Company entered into a sublicense agreement for BCMA with its then wholly owned Polish subsidiary whereby the Company will assist in preclinical and early phase clinical planning of the BCMA project. The Company's assistance includes a form of funding certain portion(s) of the preclinical development while HIO leads the regulatory and clinical development of the product in Europe. These activities are expected to be coordinated with ProMab who will be developing the product for Asia and the U.S.A. With the potential total divestiture of HIO by the Company, the sublicense agreement will have to be revisited and an amendment to the terms of the agreement may be required.

### **Clinical study initiatives**

Regulatory approvals have been granted to the Company to conduct three LDOS-47 clinical studies for the treatment of NSCLC, a Phase I combination study (LDOS001) in the U.S., a Phase I monotherapy study in Poland and a Phase II combination study in Poland, Ukraine and Hungary. In addition, the Company has also received regulatory approval for an L-DOS47 Phase Ib/II study (LDOS006) in the U.S. for a new pancreatic cancer indication.

#### *U.S. Phase I clinical study ("LDOS001")*

On April 22, 2014, the Company announced an IND approval by the FDA to commence a study for an L-DOS47 Phase I, open label, dose escalation study in combination with standard doublet therapy of pemetrexed/carboplatin in patients with Stage IV recurrent or metastatic non-squamous NSCLC. The Company has initiated three U.S. sites: Dr. Sarina Piha-Paul at the MD Anderson Cancer Center, Dr. Chandra Belani at Penn State University and the Milton S. Hershey Medical Center, and Dr. Afshin Dowlati at University Hospitals Case Medical Center.

On November 30, 2016 the Company announced that after reviewing safety data from the Phase I/II study of L-DOS47 in non-squamous non-small cell lung cancer (LDOS002), the FDA had accepted an accelerated escalation scheme for L-DOS47 dosing in the U.S. Phase I study (LDOS001) up to 12µg/kg in combination with pemetrexed/carboplatin.

The Company provided an update to the LDOS001 study at the Biotech Showcase meeting on January 10, 2017 in San Francisco. Highlights of the presentation included the following:

- No dose limiting toxicities reported at doses up to 0.78µg/kg;
- Partial responses were reported in three (3) of the first six (6) patients dosed;
- Best tumour response reported was a 44% reduction in the sum of target lesions measured; and
- Three (3) patients continued L-DOS47 monotherapy following induction therapy of L-DOS47 in combination with pemetrexed/carboplatin.

On May 26, 2017, the Penn State Cancer Institute (PSCI) announced closure of the site due to limited enrollment activity. The site has subsequently been closed and no longer actively recruiting patients.

On June 29, 2017, the MD Anderson Electronic Protocol Accrual Auditing Committee (ePAAC) met to review the LDOS001 protocol due to slow patient recruitment. The committee decided to keep the protocol open for an additional six months at which time, another review will be conducted.

On July 25, 2017 the Company announced the opening of patient screening in the third dosing cohort. After a review of safety data, the Safety Review Committee ("SRC") recommended that Helix begin enrollment of patients into the third dosing cohort of study LDOS001. Patients enrolled in the third dosing cohort will receive 1.50 µg/kg in combination with pemetrexed/carboplatin.

On September 27, 2017 the Company announced that the FDA had approved an amendment to their U.S. Phase I study, protocol LDOS001, accelerating the dose escalation phase of the study. In order to maximize the number of patients receiving a potentially active dose of L-DOS47, the study implemented an accelerated dose design up to 6µg/kg followed by a standard 3+3 design for the final two dosing cohorts, 9 and 12 µg/kg respectively.

On May 29, 2018 the Company announced the opening of patient screening in the fourth dosing cohort. After a review of safety data, the SRC recommended that Helix begin enrollment into the fourth dosing cohort. Patients enrolled in this cohort will receive LDOS47 at a dose level of 3.0 µg/kg in combination with pemetrexed/carboplatin.

On July 25, 2018 the Company announced the completion of safety review for the fourth dosing cohort and following SRC recommendations, will open patient screening in the fifth dosing cohort. Patients enrolled in this cohort will receive L-DOS47 at a dose level of 6.0 µg/kg in combination with pemetrexed/carboplatin.

On September 13, 2018 the Company announced the opening of patient screening in the sixth cohort, following SRC review of safety data from cohort five. Patients enrolled in the sixth of seven dose escalation cohorts will receive L-DOS47 at a dose level of 9.0 µg/kg in combination with pemetrexed/carboplatin.

On July 1, 2019, patient recruitment was closed due to slow enrolment with the sixth of seven cohorts enrolling only two patients rather than the expected three patients due to slow enrolment. A total of fourteen (14) patients have been dosed across 6 dose levels: 0.59 µg/kg, 0.78 µg/kg, 1.5 µg/kg, 3.0 µg/kg, 6.0 µg/kg and 9.0 µg/kg. Of twelve patients evaluable for tumour response following treatment of L-DOS47 in combination with pemetrexed/carboplatin, five (5) patients had a confirmed partial response and 4 patients experienced stable disease (as defined by RECIST v1.1), including one patient who had stable disease and remained progression-free for 13.3 months.

On May 28, 2020 at the 2020 American Society of Clinical Oncology (“ASCO”) conference, the Company published a report summarising preliminary results from the completed study. Fourteen (14) patients were enrolled across six dosing cohorts, starting at 0.59 and increasing up to 9.0 µg/kg. The MTD was not achieved as none of the patients experienced any dose-limiting toxicity (“DLT”). Fifty percent (50.0%) of patients experienced at least one treatment emergent adverse event assessed as study drug-related, with 14.3% of patients experiencing at least one grade 3/4 drug-related toxicity. Although the study was not designed specifically to assess efficacy, preliminary results showed that of 12 patients evaluable for efficacy, five patients (41.7%) had a partial response (PR), four patients (33.3%) experienced stable disease (SD) and three patients (25.0%) had progressive disease (PD). The objective response rate was 41.7%, with a clinical benefit rate is 75.0% (Table xxx). L-DOS47, in combination with pemetrexed/carboplatin, was well tolerated with promising anti-tumour activity against non-squamous NSCLC.

The Company is currently completing all necessary reports and regulatory filings to close the study. The Company hopes to have the final clinical report in three to six months subject to COVID-19 delays.

With the recent FDA approval of pembrolizumab (Keytruda®) as first line treatment for NSCLC with PD-L1>1%, either as first line or in combination with carboplatin/pemetrexed, there is an urgent need for data to demonstrate safety of LDOS47 in combination with accepted standard chemotherapies, and also in combination with immunotherapies that are being offered with growing frequency. The Company intends to file for an additional clinical study in NSCLC in combination with immunotherapies during the first quarter of 2021, subject to ongoing preclinical studies and additional financing rounds.

#### *European Phase I/II clinical study in Poland (“LDOS002”)*

On July 25, 2011, Helix announced that the Company had received approval from the Central Register of Clinical Trials at the Polish Ministry of Health to perform a European Phase I/II clinical study with L-DOS47 and, on May 14, 2012, announced that clinical site initiation and patient recruitment activities had commenced for its European Phase I/II clinical study of L-DOS47. On October 23, 2012, the Company announced that its first patient had been enrolled and the first dose had been administered in this study.

The study was conducted at five Polish centers under the direction of Dr. Dariusz Kowalski at The Maria Skłodowska-Curie Memorial Cancer Centre & Institute of Oncology as the overall coordinating investigator, together with four other principal investigators: Prof. Cezary Szczylik, MD, PhD at the Military Medical Institute, Prof. Elzbieta Wiatr, MD, PhD at the National Tuberculosis and Lung Diseases Research Institute, Dr. Aleksandra Szczensa, MD, PhD at the Mazovian Center of Pulmonary Diseases and Tuberculosis in Otwock and Prof. Rodryg Ramlau, MD, PhD at Med. Polonia Hospital Poznan.

The study was conducted in patients with inoperable, locally advanced, recurrent or metastatic, non-squamous stage IIIb/IV NSCLC. The study recruited patients eligible for inclusion into escalating doses of L-DOS47 given as a monotherapy. The study utilized an open-label design, allowing for periodic status updates through its course. The study was intended to demonstrate valuable safety and proof-of-concept efficacy data for L-DOS47.

In the Phase I portion of the study, patients received weekly doses of L-DOS47, administered as an intravenous infusion over 14 days, followed by seven days' rest (one treatment cycle is three weeks), in order to determine the MTD of L-DOS47. The Phase II portion of the study evaluated the preliminary efficacy of L-DOS47.

In the Phase I component of the study, a total of 55 male and female patients, at least 18 years of age, with histologically confirmed non-squamous NSCLC were dosed at 16 L-DOS47 dose levels. Patients were required to have an Eastern Cooperative Oncology Group performance status of 0 – 2 at the screening visit for this study and have at least one site of measurable disease per RECIST v1.1.

The Phase II component enrolled the same patient population as the Phase I at an L-DOS47 dose of 13.55µg/kg. Patients in the study were dosed twice weekly over 14 days (Days 1, 4, 8, 11) followed by a 7-day rest. A total of 21 patients were dosed in the first stage of the Phase II component of the study.

To date, the Company completed four interim data reviews in connection with the LDOS002 Phase I study and one final review of Phase II study.

On October 15, 2013, the Company announced the completion of an interim data review of the first four cohorts for this study. The release stated that L-DOS47 was well tolerated for all patients treated within all cohorts. None of the treatment related adverse events reported to date met the definition of a dose-limiting toxicity. Adverse events reported as of that date were those normally expected for the population under study.

A review of available pharmacokinetic ("PK") and immunogenicity data showed that these data so far, were consistent with trends seen within pre-clinical animal studies of L-DOS47. Results from these reviews, together with safety data provided guidance on the treatment schedule and dosing for the Phase II portion of the study.

Based on Radiologic Evaluations, patients assigned a status of "Progressive Disease" following any such assessment were withdrawn from the study. At least one patient in each of the four cohorts dosed had a radiological assessment of "Stable Response". Duration of treatment increased with each dose escalation up to Cohort 4. One patient in Cohort 3 was dosed for 6 cycles without disease progression. None of the patients treated to date had a partial or complete response as defined by RECIST v1.1 definition.

On September 30, 2014, the Company announced the completion of a further interim data review for the first eight cohorts for the LDOS002 study. The review included all available data, including patient demographics, safety assessments, PK data, immunogenicity and radiological tumour assessments. The following observations were made:

- Adverse events reported were expected for investigational product and population under study;
- No Dose Limiting Toxicities ("DLTs") have been reported;
- Stable disease observed in radiological assessments of 12 of 24 (50%) of patients treated; and
- Two patients completed six cycles of treatment each.

On September 8, 2015, the Company announced the presentation and update of the ongoing clinical study LDOS002 for the Company's drug candidate L-DOS47 during the 16th World Conference on Lung Cancer held in Denver Colorado. The presentation included the following data:

- 40 patients were enrolled in the first twelve dosing cohorts;
- L-DOS47 was well tolerated at the dose levels up to 4.33 µg/kg;
- No DLTs were reported for Cohorts 1-12;
- One (1) DLT was reported for Cohort 13;
- adverse events reported to date were expected for the population under study;
- 21 of the 40 patients had an overall response of stable disease based on radiological assessment after completing two cycles of L-DOS47;
- 11 of these 21 patients continued with a response of stable disease based on radiological assessment after completing four cycles of L-DOS47;
- one (1) patient in cohort 9 was dosed for 10 cycles (approximately seven (7) months) without disease progression;
- the study is currently enrolling patients in the thirteen-dosing cohort (5.76 µg/kg).

On December 6, 2016, the Company presented the following LDOS002 Phase I data for the Company's drug candidate L-DOS47 during the 17<sup>th</sup> World Conference on Lung Cancer held in Vienna, Austria:

- 90 patients were consented and screened for participation in the study;
- 55 patients were administered at least one dose of L-DOS47 at dose levels ranging from 0.12 to 13.55µg/kg;
- 21 patients completed four treatment cycles and 16 patients were administered additional L-DOS47 cycles;
- Comparatively, patients in cohorts 13 to 16 (5.76 to 13.55µg/kg) were exposed to more L-DOS47 for a longer duration without a significant change to the safety profile of L-DOS47 compared to the other dosing cohorts;
- 44, or 80% of the patients in the safety population had at least one treatment emergent adverse events;
- L-DOS47 did not elicit a dose-dependent release of cytokines at doses up to 13.55µg/kg
- The MTD of L-DOS47 was not reached in the Phase I component of study LDOS002 at doses administered up to 13.55µg/kg;
- L-DOS47 was well tolerated at all dose levels up to 13.55µg/kg.
- A dose response trend was observed when comparing the percentage of patients who were progression free at 16 weeks across dose ranges;
- A similar trend was observed when comparing the percentage of patient who had an overall tumour response of Stable Disease (as defined in RECIST v1.1) and had a reduction in the sum of target lesions;
- 11 of 14 or 79% of patients in the highest dosing cohorts (5.76 to 13.55µg/kg) had an overall tumour response of Stable Disease following the administration of two cycles of L-DOS47;
- Seven (7) of 14 or 50% of patients in the same dosing cohorts had an overall tumour response of Stable Disease and a reduction in the sum of target lesions and 57% of patients were progression free for greater than 16 weeks.

On March 8, 2016, the Company announced the following approved changes by the central ethics committee overseeing the Phase I/II study in Poland as it relates to the Phase II component of the study, which the Company intends to initiate:

- There will be no further escalations of L-DOS47 past cohort 16. If there are no further dose limiting toxicities, the cohort 16 dose, 13.55 µg/kg, will be the dose administered to patients in the Phase II dose.
- The safety profile supports a more frequent administration of L-DOS47. After reviewing safety, pharmacokinetic and immunogenicity data, L-DOS47 will be dosed twice weekly over 14 days (Days 1, 4, 8, 11) followed by a 7-day rest in the Phase II study.
- The number of patients in the Phase II study will be increased to 45 patients. Based on Simon's optimal two-stage design, 17 evaluable patients will be enrolled in the first stage of the Phase II component of the study. If there is/are ≥ 1 response(s) out of these initial 17 evaluable patients, 22 additional evaluable patients will need to be enrolled. To obtain 39 patients evaluable for response, enrolment of approximately 45 patients are needed.

On April 21, 2016, the Company announced the approval by the Trial Steering Committee to initiate the Phase II component of the LDOS002 study. On April 28, 2016, the Company announced the enrolment of the first patient in the Phase II component of the LDOS002 study. The first Phase II patient was dosed on May 10, 2016 and had now completed their first L-DOS47 cycle.

Although the Phase II intensified L-DOS47 regimen was well tolerated by patients enrolled in the first stage of the study, an improvement in potential benefit to patients compared to the Phase I regimen (L-DOS47 dosed once weekly over 14 days (Days 1, 8) followed by a 7-day rest) was not observed. The potential complications associated with more frequent intravenous administrations in LDOS002 did not support the potential benefit to patients, past cycle four. As a result, the LDOS002 protocol was amended to limit the number of dosing cycles to a maximum of 6 cycles.

Following the review of clinical data collected to date, L-DOS47 continues to be well tolerated. The data also suggests that L-DOS47 may provide a clinical benefit for certain patients. After completion of enrolment for the first stage of the Phase II component of study LDOS002 (n=21), a Trial Steering Committee Meeting was held on December 19, 2017 to review safety and efficacy data to determine next steps. A recommendation was made by the committee to stop further enrolment into the second stage of the Phase II component of the study due to lack of efficacy as defined by protocol (≤ 1 objective response).

The final clinical study report was completed and signed off in June 2020.

#### *Phase II clinical study ("LDOS003")*

A potential secondary yet unproven aspect of L-DOS47 action is the observation that an acidic pH microenvironment (< pH 6.8) may limit the effectiveness of weakly basic cytotoxic drugs employed in treatment of lung and other solid tumours. An acidic microenvironment is associated with protonation of these agents and decreased uptake and alkalisation can result in enhanced agent uptake and cytotoxicity. Furthermore, extracellular acidity may also inhibit the active transport of some drugs. This raises the possible application of L-DOS47 to combination cancer therapies with agents which have little or no overlapping toxicities.

This study is designed to determine the possible chemo-enhancing properties of L-DOS47. The possibility of combining L-DOS47 with a weakly basic agent like vinorelbine may improve therapeutic outcomes for cancer patients. The vinorelbine/cisplatin combination is used as a first-line treatment for lung adenocarcinoma.

The Company has initiated a Phase II, open-label, randomized study in male and female patients aged ≥ 18 years old with metastatic lung adenocarcinoma. The staging will be conducted according to Tumour Node Metastases (TNM), 8<sup>th</sup> Edition. In Part 1 of the study (Dose Escalation), patients will receive eight (8) doses of L-DOS47 over four (4) cycles. On Day 1 and Day 8 of each cycle, L-DOS47 (administered as an intravenous ("IV") infusion) will be administered 24 hours before vinorelbine/cisplatin. Once the maximum tolerated dose of L-DOS47 as an adjunct to vinorelbine/cisplatin is determined, patients in Part 2 of the study (Randomized Treatment) will be randomly assigned to receive L-DOS47 in combination with vinorelbine/cisplatin or vinorelbine/cisplatin alone. Six (6) sites have been identified in Poland and the Ukraine to participate in Part 1. Initial Competent Authority approval was received for Ukraine in February 2018, and a further amendment approval was received in March 2018. Ethics approvals for three Ukraine sites are already in receipt since end of February 2018. Competent Authority and Ethics Committee approvals for three sites in Poland were received in April 2018. Site selection activities to add a third country, Hungary, to the randomized treatment part of the study were completed in March 2018.

The Company had placed the LDOS003 study on hold since April 2018 due to the Company's limited financial resources at the time. Activities resumed in November 2018, and Competent Authorities approval for Hungary was received on November 29, 2018. First sites were initiated in Ukraine and Poland on December 13, 2018 and January 24, 2019, respectively. The first subject entered into screening for the Part I dose escalation phase of the study was in Ukraine on February 19, 2019, and the first study drug dose was subsequently initiated on March 6, 2019. Safety data review for the first cohort (6 µg/kg) was completed by the Trial Steering Committee on April 15, 2019, with a recommendation to escalate to the next cohort dose level (9 µg/kg). The Trial Steering Committee completed safety data review for the second cohort of patients (9 µg/kg) on July 18, 2019, with a recommendation to escalate to the next cohort dose level (12 µg/kg). To date, two (2) patients have been dosed at 12 µg/kg on October 8 and 16, 2019, respectively. The third cohort has not been completed due to a hold on recruitment, as a result of a shortage in the required vinorelbine dosages from the manufacturer.

The Company has determined that it will not be moving forward with Part 2 of the study unless certain clinical objectives are met in Part 1 of the study and sufficient capital is obtained, or the Company enters into a co-development partnership with a third party.

As shortages of required vinorelbine dosages from the manufacturer are expected to continue through to 2021, the Company has made the decision to terminate further recruitment and proceed to data analysis.

In the event that both conditions were met, the Company does not have sufficient supply of L-DOS47 to complete Part 2 of the study and as a result, would have to manufacture additional drug product. Manufacturing of any new drug product could take up to one year and would be subject to successful quality assurance release and availability.

Vinorelbine/cisplatin chemotherapy combination in the US has become infrequent due to the rapidly evolving treatment landscape and the growing prominence of immunotherapies such as Keytruda®. The Company had commenced this study based on the use of vinorelbine/cisplatin chemotherapy combinations in Eastern Europe and Asian markets.

#### *U.S. Phase Ib/II clinical study (“LDOS006”)*

Following a June 4, 2018 Scientific and Strategic Advisory Board (“SSAB”), in collaboration with Dr. Von Hoff at Translational Genomics Research Institute in Scottsdale, Arizona, the Company began early development of a Phase Ib/II study, L-DOS47 given in combination with doxorubicin, for previously treated advanced pancreatic cancer. Pancreatic cancer accounts for approximately 3% of all cancers in U.S. for which there are currently few treatment options. An IND was filed on July 8, 2019 and the subsequent approval of the FDA was received on August 6, 2019. The first site and Principal Investigator, Dr. Erkut Borazanci at HonorHealth in Scottsdale, Arizona, was initiated on November 26, 2019. A subsequent amendment to improve logistics of trial conduct was submitted on December 3, 2019.

The study is entitled “A Phase Ib/II Study of the Microenvironment Modifier L-DOS47 plus Doxorubicin for the Treatment of Patients with Previously Treated Advanced Pancreatic Cancer”. The Phase Ib portion of the study involves three dose escalating cohorts (3, 6 and 9 µg/kg) enrolling a total of nine (9) patients. The Phase II portion of the study will enroll an additional eleven (11) patients depending on meeting safety and efficacy criteria.

On December 11, 2019, the Company announced that patient enrollment and screening had commenced. To date, five (5) patients have been enrolled in the study. Of these patients, the initial two (2) patients withdrew prior to completing the initial safety evaluation period, two (2) patients who have safely completed the safety evaluation period but have since withdrawn, and one (1) patient currently active in the safety evaluation period of the study. Once the third patient has completed the safety evaluation period, the Safety Review Committee will conduct an evaluation of all safety data for the first dosing cohort (3 µg/kg) before opening recruitment to the subsequent dosing cohort. The Company is targeting completion of the Phase Ib enrollment by the end of 2020 and Phase II patient enrollment by the end of 2021. In the event cohort expansion is required due to adverse events during the Phase 1b dosing, the timeline may be extended.

The Company is also preparing for delay in recruitment due to the COVID-19 pandemic. The Company has begun feasibility and site qualification activities with the prospect of adding one to two additional sites.

The Company does not have sufficient supply of L-DOS47 to fully complete the study. The Company recently contracted with a third-party manufacturer to produce new drug product that could take up to one year and would be subject to successful quality assurance release and availability. The Company’s current supply of L-DOS47 continues to be subjected to stability assays every six months. In the event that any of the stability assays (current batch or new production batch) does not pass, the Company’s clinical studies and any planned research and development programs would likely face delays and possibly be cancelled which could impair the current and future value of the business.

Given the Company’s limited current cash resources and the possibility of not being able to obtain additional financing on a timely basis, the Company may be required to reduce, delay or cancel one or more of its planned research and development programs, including clinical studies, along with further reductions in overhead, any of which could impair the current and future value of the business.

#### **Commercialization**

The Company’s DOS47 commercialization objective is to eventually enter into a strategic partnering alliance with a large pharmaceutical company, on an individual or multiple drug candidate basis, such as L-DOS47 or any potential new DOS47 drug product candidate. The Company has retained Deloitte Corporate Finance as its strategic advisor to explore partnering and licensing opportunities. The intention of Company is to enter a structured process that will include preparing the Company to have discussions with potential partners, engaging in dialogue with a targeted group of qualified partners and licensees, and entering negotiations on a prospective partnership, alliance or licensing transaction. In the meantime, the Company will continue to gather as much value-adding clinical data/findings, which demonstrate the safety and efficacy of L-DOS47 in patients or any other new potential DOS47 drug candidate so as to maximize value for shareholders when entering into a strategic partnering alliance.

## **Market and Competition**

### *Non small cell lung cancer*

Based on information published in “Key Statistics for Lung Cancer” by the American Cancer Society ([www.cancer.org](http://www.cancer.org)), lung cancer accounts for about one out of four of all cancer deaths and is by far the leading cause of cancer death among men and women in the U.S. It is estimated that in 2020 there will be over 228,820 new lung cancer cases and 135,720 may die from the disease. Of these cases, over 80% are of the non small cell lung cancer (NSCLC) type.

The treatment options for metastatic NSCLC has changed significantly in the last few years due to the clinical success of Immunotherapies such as immune checkpoint inhibitors that target Programmed Death 1 (“PD-1”) or its ligands. On March 4, 2015 the FDA approved Nivolumab, the generic name for the trade drug named Opdivo®, which targets PD-1 for the treatment of metastatic squamous NSCLC with progression on or after platinum-based chemotherapy. On October 2, 2015, the FDA granted accelerated approval for Pembrolizumab, the generic name for the trade drug named Keytruda®, which targets PD-1 to treat patients with advanced metastatic NSCLC whose disease has progressed after other treatments and with tumours that express PD-L1.

As of March 2017, the FDA had approved five checkpoint inhibitor drugs: ipilimumab (Yervoy®), pembrolizumab (Keytruda®), nivolumab (Opdivo®), atezolizumab (Tecentriq®) and avelumab (Bavencio®).

On May 10, 2017, the FDA granted accelerated approval to pembrolizumab (KEYTRUDA®, Merck and Co., Inc.) in combination with pemetrexed and carboplatin for the treatment of patients with previously untreated metastatic non-squamous non-small cell lung cancer (NSCLC). Approval was based on a cohort (G1) of patients enrolled in an open-label, multicenter, multi-cohort study (KEYNOTE-021). As a result of these developments in the treatment of NSCLC, the Company is currently reassessing its L-DOS47 clinical program given that: (a) its target therapeutic indication, being inoperable, locally-advanced, recurrent or metastatic NSCLC, may be a good candidate to combine with the emerging best-in-class immunotherapies; and (b) leading therapeutics for such oncology applications have commonly been high revenue generators for the pharmaceutical sector. The FDA recently approved pembrolizumab (Keytruda®) as first line treatment for NSCLC with PD-L1>1%, either as first line or in combination with carboplatin/pemetrexed. Consequently, there is an urgent need for data to demonstrate safety of LDOS47 in combination with accepted standard chemotherapies, and also in combination with immunotherapies that are being offered with growing frequency.

### *Pancreatic Cancer*

Pancreatic cancer remains a deadly disease of significant unmet medical needs. American Cancer Society estimates 57,600 people will be diagnosed with the disease in the US with 47,050 death in 2020. The most common type of pancreatic cancer is exocrine in nature. And about 95% of these exocrine cancers are adenocarcinomas.

Treatment options for late stage metastatic pancreatic cancer patients are limited. Surgery is used only for symptoms relief and so is radiation. Chemotherapy remains primary mode of therapy. Drug such as Gemcitabine is widely used either alone or in combination with erlotinib (Tarceva), capecitabine, cisplatin or nab-paclitaxel. Other chemo-cocktails are also possible depending on patient status. If this line of therapy is not effective, other combination such as oxaliplatin and fluoropyrimidine may be used.

Unlike certain lung cancer or melanoma, checkpoint therapy clinical studies in pancreatic patients have largely been unsuccessful. While the exact reason(s) are still be elucidated, many have pointed to the unique structural and immune environment found this cancer as the reasons why antibody-based immunotherapy may not be successful. L-DOS47 with its unique method of modifying tumor environment represent a new front to tackle this difficult condition.

Technological competition from pharmaceutical companies, biotechnology companies and university researchers, is intense and is expected to continue to be very intense. While the Company is leading its competitions in clinical development of a therapy that targets tumor acidosis, some potential competitors have substantially greater product development capabilities and financial, scientific, marketing and human resources than the Company.

## **The Biphaxis™ Topical Formulation System**

The Biphaxis™ Topical Formulation System is a platform technology which the Company acquired and further developed for microencapsulating therapeutic compounds in multilayered, lipid-based microvesicles. These microvesicles have complex structures that include a variety of compartments into which drug molecules can be integrated. The principal application of the technology is in the preparation of topical dosage forms for the dermal (into the skin) or mucosal (into the mucosal tissues) delivery of large molecular weight drug compounds.

### *Topical Interferon Alpha-2b*

Due to a lack of funding, a decision was made by the Company in fiscal 2012 to downsize and eventually close the Saskatoon laboratory which supported the Topical Interferon Alpha-2b drug development program.

On December 23, 2016, the Company announced, it signed an exclusive out-license agreement with Xisle for the Company's late-stage, Biphasix™ technology platform, including the lead product candidate, interferon alpha. Xisle is responsible for the continued clinical development and subsequent commercialization of the product for the treatment of HPV-induced, low-grade, cervical intraepithelial lesions. Under the terms of the agreement, Xisle paid an up-front fee of \$125,000 USD and agreed to pay subsequent milestone payments as they advance the technology to registration and market approvals and royalties. As part of the agreement, Helix retains marketing rights for Belarus, Bulgaria, Czech Republic, former Eastern Germany, Hungary, Moldova, Poland, Romania, Russia, Slovakia and Ukraine. In addition, the Company also retains non-exclusive rights for co-promotion in Canada.

The Company subsequently assigned the marketing rights which it retained over to HIO in Poland pursuant to an agreement between the Company and HIO with the agreement being subject to the restrictions and limitations associated with the out-license agreement signed between the Company and Xisle. In addition, HIO would be responsible for commercialization with milestone and royalty payments to be paid back to the Company upon successful product development through to commercialization.

As part of the debt cancellation agreements, announced by the Company on June 25, 2020, the Company and HIO have agreed to terminate both the BiPhasix™ license agreement. As a result, all transferred assets related to BiPhasix™ have been automatically reassigned and transferred from HIO back to the Company without any formality.

As a result, the Company will now assess what next steps to take, if any, with the BiPhasix™ antibody.

### SELECTED FINANCIAL INFORMATION AND SUMMARY OF QUARTERLY RESULTS

The Company reported a consolidated net loss and total comprehensive loss of \$2,594,000 (\$0.02 loss per common share) and \$7,060,000 (\$0.05 loss per common share), respectively for the three and nine-month period ended April 30, 2020. For the three and nine-month periods ended April 30, 2019, consolidated net loss and total comprehensive loss of totalled \$2,071,000 (\$0.02 loss per common share) and \$5,358,000 (\$0.05 loss per common share), respectively.

Fluctuations in net loss and total comprehensive loss is mainly the result of cash reserves available to be deployed on ongoing research and development activities and operating, general and administration expenses.

The Company experienced a working capital deficiency for several quarters until August 21, 2019 when the Company closed the first of a series of three private placements which included January 13, 2020 and March 12, 2020 for total gross proceeds of approximately \$16,000,000. A portion of the private placement financings included the total disposition of a 49.0% stake of the Company's Polish subsidiary, HIO. On April 30, 2020 the Company owned 51.0% which was subsequently reduced to 42.5% after HIO, on July 8, 2020, completed a direct private placement with an investor. See *SUBSEQUENT EVENTS* section below.

(thousand \$, except per share information)								
	Q3	Q2	Q1	Q4	Q3	Q2	Q1	Q4
	2020	2020	2020	2019	2019	2019	2019	2018
Research and development expense	1,523	1,649	1,429	1,317	1,330	1,301	998	1,084
Operating, general and admin expense	862	576	548	735	495	360	239	415
Net loss from continuing operations	-2,396	-2,212	-1,987	-2,040	-1,845	-1,600	-1,228	-1,506
Net loss from discontinued operations	-198	0	0	0	0	0	0	0
Net loss and total comprehensive loss	-2,594	0	0	0	0	0	0	0
Loss per share - basic & fully diluted	-0.02	-0.02	-0.02	-0.02	-0.02	-0.02	-0.01	-0.02
Cash	4,989	1,988	1,610	94	816	235	765	229
Working capital / (deficiency)	3,826	890	538	-3,465	-2,148	-1,937	-2,004	-2,039

The Company's L-DOS47 clinical studies in NSCLC have been in the later stages of patient enrollment, within their respective clinical phases, and as a result the Company has incurred lower spending in these clinical studies. After having been approved by the FDA in August of 2019 for a new IND clinical study in patients with advanced pancreatic cancer, first patient enrollment for this clinical study commenced December 2019. Costs associated with the new pancreatic clinical study in addition to manufacturing costs to produce additional drug substance has resulted in higher research and development costs in the recent three quarters.

Operating and general expenditures after the Company's cost reduction initiatives ending in early 2019 have increased in the last four quarters. In both Q3 2020 and Q4 2019, operating, general and administrative expenses were impacted by stock-based compensations expense for options granted. In addition, in Q4 2019 the Company paid bonuses to both the CEO and CFO. Gradually starting in Q1 2020 and continuing through to Q3 2020 operating, general and administration were also impacted by higher expenses associated with various third-party advisor services such as investor and media relations, legal, business

development activities and investment banking services. The Company has been in discussion with various advisory groups as it pursues a listing on a recognized U.S. stock exchange, like the Nasdaq.

## RESULTS FROM OPERATIONS

### *Net loss from continuing operations*

The Company reported a consolidated net loss and total comprehensive loss of \$2,594,000 (\$0.02 loss per common share) and \$7,060,000 (\$0.05 loss per common share), respectively for the three and nine-month period ended April 30, 2020. For the three and nine-month periods ended April 30, 2019, consolidated net loss and total comprehensive loss of totalled \$2,071,000 (\$0.02 loss per common share) and \$5,358,000 (\$0.05 loss per common share), respectively.

### *Research & development*

Research and development costs for the three and nine-month periods ended April 30, 2020 totalled \$1,523,000 and \$4,601,000, respectively (\$1,331,000 and \$3,631,000 respectively for the three and nine-month periods ended April 30, 2019).

The following table outlines research and development expenditures and investment tax credits for the Company's significant research and development projects:

	For the three-month periods ended April 30		For the nine-month periods ended April 30	
	2020	2019	2020	2019
L-DOS47	\$ 1,141,000	\$ 1,054,000	\$ 3,616,000	\$ 2,703,000
CAR-T	54,000	–	54,000	333,000
Corporate research and development expenses	180,000	155,000	441,000	380,000
Trademark and patent related expenses	126,000	110,000	364,000	178,000
Depreciation expense	13,000	12,000	38,000	37,000
Stock-based compensation expense	9,000	–	88,000	–
	\$ 1,523,000	\$ 1,331,000	\$ 4,601,000	\$ 3,631,000

L-DOS47 research and development expenses for the three and nine-month periods ended April 30, 2020 totalled \$1,195,000 and \$3,670,000, respectively (April 30, 2019 - \$1,054,000 and \$2,703,000, respectively). L-DOS47 research and development expenditures relate primarily to the Company's LDOS001 Phase I clinical study in the U.S., the LDOS003 Phase II clinical study in Poland and the Ukraine and the Company's new LDOS006 Phase Ib/II pancreatic clinical study in the U.S. The increase in L-DOS47 expenditures in Q3 fiscal 2020 when compared to Q3 fiscal 2019 reflects an increase of approximately \$161,000 in manufacturing activity to produce additional drug substance along with an increased spend of approximately \$386,000 in the Company's newly launched pancreatic clinical study in the U.S. The Company commenced enrollment in the new pancreatic clinical study in December 2019. Offsetting the increased spend in the quarter was a reduction in spending of \$279,000 related to the Company's LDOS001 clinical study of L-DOS47 in combination with pemetrexed/carboplatin in the U.S. and a further reduction of \$133,000 related to a research collaboration project that ended involving the Moffitt Cancer Centre ("Moffitt"). The Company's LDOS001 clinical study has completed enrollment and the Company is working on finalizing data for reporting. The LDOS003 clinical study had little impact on spending in the quarter. The Company had previously made the decision to not advance the study without entering a co-development partnership with a third party and therefore previously made the decision to terminate further recruitment and proceed to data analysis.

For the nine-month period ending Q3 2020 when compared to the six-month period ended Q3 2019 the increase in spending mainly reflects drug substance manufacturing spend of \$498,000, costs associated with the new LDOS006 pancreatic trial in the U.S. of \$783,000 and costs associated to finalize and report on LDOS001 of \$252,000. Offsetting the increased spend was a reduction in spending of \$367,000 related to the Company's LDOS001 and a further reduction of \$204,000 related to the Moffitt research collaboration.

The supporting L-DOS47 expenditures include costs associated with the Company's research laboratory in Edmonton, Alberta, Canada which includes employee wages and benefits, fixed overhead costs such as rent, light, heat, water and variable costs such as laboratory consumables. Also included are costs associated with the manufacture of L-DOS47 drug substance/product and related assays from third party suppliers and costs associated with running and managing the L-DOS47 clinical trials in the various geographic jurisdiction. These include wages and benefits of employees involved in overseeing third-party vendors who monitor the trials on behalf of the Company in addition to all patient clinical study costs incurred at the various clinics where patients are being dosed.

CAR-T research and development expenses for both the three and nine-month periods ended April 30, 2020 totalled \$54,000 and \$54,000, respectively (three and nine-month periods ended April 30, 2019 - \$333,000 and \$333,000, respectively). The Company's collaboration with ProMab Biotechnologies Inc. ("ProMab") has been impacted by the Coronavirus pandemic and as such certain planned activities have been deferred.

Trademark and patent related expenses for the three and nine-month periods ended April 30, 2020 totalled \$126,000 and \$364,000, respectively (three and nine-month periods ended April 30, 2019 - \$110,000 and \$178,000, respectively). The Company continues to ensure it adequately protects its intellectual property.

Stock based compensation expense for the three and nine-month periods ended April 30, 2020 totalled \$9,000 and \$88,000, respectively (three and nine-month periods ended April 30, 2019 - \$nil and \$nil, respectively). The amount represents the expense associated with the vesting of stock options that were granted, over their vesting period.

### **Operating, general and administration**

Operating, general and administration expenses for the three and nine-month periods ended April 30, 2020 totalled \$862,000 and \$1,986,000, respectively (\$495,000 and \$1,094,000 respectively for the three and nine-month periods ended April 30, 2019). The increase is mainly the result of higher expenses associated with various third-party advisor services such as investor and media relations, legal, business development activities and investment banking services. The Company has been in discussion with various advisory groups as it pursues a listing on a recognized U.S. stock exchange, like the Nasdaq.

The following table outlines operating, general and administration costs expensed for the following periods:

	For the three-month periods ended April 30		For the nine-month periods ended April 30	
	2020	2019	2020	2019
Wages and benefits	\$ 109,000	\$ 112,000	\$ 327,000	\$ 320,000
Director fees	40,000	42,000	120,000	122,000
Third-party advisors	396,000	280,000	978,000	462,000
Other general and administrative	101,000	59,000	278,000	183,000
Depreciation expense	–	2	1,000	5,000
Stock-based compensation expense	216,000	–	282,000	2,000
	\$ 862,000	\$ 495,000	\$ 1,986,000	\$ 1,094,000

Stock based compensation expense for the three and nine-month periods ended April 30, 2020 totalled \$216,000 and \$282,000, respectively (three and nine-month periods ended April 30, 2019 - \$nil and \$2, respectively). The amount represents the expense associated with the vesting of stock options that were granted, over their vesting period.

### **Net loss from discontinued operations**

The Company reported a net loss from discontinued operations of \$198,000 and \$465,000, respectively for the three and nine-month period ended April 30, 2020.

During the year, the Company disposed of a 49.0% ownership in its Polish subsidiary, Helix Immuno-Oncology S.A. (“HIO”), bringing the Company’s total ownership interest in HIO as at April 30, 2020 to 51.0%. Subsequent to the Company’s third fiscal quarter on June 25, 2020, the Company made the following announcements relating to its Polish subsidiary:

- Entered into agreements with HIO, pursuant to which the Company cancelled an aggregate amount of approximately \$2.7 million of intercompany debt owed to the Company by HIO. As a result, all transferred assets related to Biphasix and V-DOS47 have been automatically reassigned and transferred from HIO back to the Company without any formality. The Company has also ceased financing HIO with immediate effect.
- The Company approved an increase in share capital of HIO and the issuance of up to 2.2 million Series B ordinary shares in the capital of HIO to enable it to issue up to 2.2 million Series B ordinary shares by way of a private placement financing for aggregate gross proceeds of approximately 2.97 million Polish zloty. HIO completed the private placement on July 8, 2020 and as a result the Company’s shareholding in HIO has been reduced to approximately 42.5% of the outstanding shares of HIO.
- The Company accepted a non-binding term sheet offer from CAIAC Fund Management AG, in its capacity as designated trustee of an alternative investment fund that is currently in the process of being established and authorized by the Financial Market Authority in Liechtenstein (“FMA”). The terms of the offer provide for the Company to sell its remaining holdings in HIO for gross proceeds of 6.7 million Polish zloty (approximately \$2.3 million). The transaction is scheduled to close on Aug. 31, 2020, and is subject to a number of conditions, including the approval of the fund by the FMA; the raising of a minimum 7.3 million Polish zloty by the fund as well as regulatory approval of the transaction, if required. There can be no assurance that the closing of the divestment will occur on the terms set out herein or at all.

## **CRITICAL ACCOUNTING ESTIMATES**

The preparation of financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, revenue and expenses and the related disclosures of contingent assets and liabilities and the determination of the Company's ability to continue as a going concern. Actual results could differ materially from these estimates and assumptions. The Company reviews its estimates and underlying assumptions on an ongoing basis. Revisions are recognized in the period in which the estimates are revised and may impact future periods.

The Company has also assessed the impact of COVID-19 on estimates and critical judgement. Although the Company expects COVID-19 related disruptions to continue into the Company's fiscal 2021 year, the Company believes that the long-term estimates and assumptions do not require significant revisions. Although the Company determined that no significant revisions to such estimates, judgements or assumptions were required, the pandemic is fluid and given the inherent uncertainty at this time, revisions may be required in future periods to the extent that the negative impacts on the Company's business operations arising from COVID-19 continue or become worse. Any such revision could result in a material impact on the Company's financial performance and financial condition.

The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to the Company's financial statements have been set out in Note 1 of the Company's condensed unaudited consolidated financial statements for the three and nine-month periods ended April 30, 2020 and 2019.

## **SIGNIFICANT ACCOUNTING POLICIES**

The significant accounting policies used in preparing the Company's consolidated financial statements are described in Note 2 of the Company's audited consolidated financial statement for the fiscal year ended July 31, 2019, except for those related accounting policies and methods of computation related to any new accounting standards and pronouncements.

## **NEW ACCOUNTING STANDARDS AND PRONOUNCEMENTS NOT YET ADOPTED**

There are no new accounting standards and pronouncements issued but not yet effective up to the date of issuance of the Company's interim consolidated financial statements that are expected to have a material impact on the Company.

## **LIQUIDITY AND CAPITAL RESOURCES**

Since inception, the Company has mainly relied on financing its operations from public and private sales of equity. The Company does not have any credit facilities and is therefore not subject to any externally imposed capital requirements or covenants. The Company manages its liquidity risk by continuously monitoring forecasts and actual cash flow from operations and anticipated investing and financing activities.

The Company reported a consolidated net loss and total comprehensive loss including non-controlling interest of \$2,594,000 for the three-month period ended April 30, 2020 (April 30, 2019 - \$2,071,000), and \$7,060,000 for the nine-month period ended April 30, 2020 (April 30, 2019 - \$5,358,000). As at April 30, 2020 the Company had working capital of \$3,826,000, shareholders' equity of \$3,934,000 and a deficit of \$178,427,000. As at July 31, 2019 the Company had a working capital deficiency of \$3,534,000, shareholders' deficiency of \$3,281,000 and a deficit of \$171,531,000.

The Company experienced a working capital deficiency for several quarters until August 21, 2019 when the Company closed the first of a series of three private placements which included January 13, 2020 and March 12, 2020 for total gross proceeds of approximately \$16,000,000. A portion of the private placement financings included the total disposition of a 49.0% stake of the Company's Polish subsidiary, HIO. On April 30, 2020 the Company owned 51.0% which was subsequently reduced to 42.5% after HIO, on July 8, 2020, completed a direct private placement with an investor.

The Company previously disclosed its intentions to fully divest its interest in its Polish subsidiary in order to raise additional capital to further fund the Company's clinical development programs while still retaining licensing arrangements for future royalties and milestone payments.

On June 25, 2020, the Company announced the receipt and acceptance of a non-binding offer from CAIAC Fund Management AG, in its capacity as designated trustee of an alternative investment fund that is currently in the process of being established and authorized by the Financial Market Authority in Liechtenstein ("FMA"). The terms of the offer provide for the Company to sell its remaining holdings in HIO for gross proceeds of 6.7 million Polish zloty (approximately \$2.3 million). The transaction is scheduled to close on Aug. 31, 2020, and is subject to a number of conditions, including the approval of the fund by the FMA; the raising of a minimum 7.3 million Polish zloty by the fund as well as regulatory approval of the transaction, if required. There can be no assurance that the closing of the divestment will occur on the terms set out herein or at all.

In addition, the Company has been in discussions with various capital market firms, both in the U.S. and Canada, with the goal of raising additional capital to qualify the Company for a listing on a U.S. stock exchange such as NASDAQ in order to further advance the Company's clinical development programs.

In order for the Company to advance its various currently planned preclinical and clinical research and development activities, its collaborative scientific research programs and pay for its overhead costs, the Company will need to raise approximately \$15,000,000 to \$20,000,000. The Company is projecting average monthly fixed overhead costs of approximately \$375,000 per month. This amount does not include the costs related to any of the Company's third-party activities such as clinical studies, collaborative research activities, contract manufacturing and any of the additional costs associated with the Company's objective to list on the Nasdaq.

The Company currently has several clinical studies (see *Clinical Study Initiatives* above for details) in various stages of development. Due to slow enrollment, the Company stopped LDOS001 enrollment and has been working on the final clinical study report. The Company is forecasting approximately \$366,000 to fully complete the study and report. The Company previously forecasted LDOS003 as a large randomized study but concluded that it would not move forward with the randomized portion of the study unless the Company entered into a co-development partnership with a third party. The Company is forecasting approximately \$300,000 to fully complete the study and report.

The Company received IND approval by the FDA to conduct a Phase Ib/II study (LDOS006) in the U.S., L-DOS47 in combination with doxorubicin, for previously treated advanced pancreatic cancer. Patient enrollment commenced December 2019. The Company has forecasted a total cost of approximately \$6,000,000 in order to fully complete the study, which is projected to be fully completed and reported on by the first half of calendar 2022.

In support of the clinical study programs, the Company will need to manufacture drug product. The Company originally determine that it would likely need an entire new manufacturing batch but has since determine that a current batch could be repurposed. The Company is projecting a cost of approximately \$815,000 which includes all assay development and stability studies. The manufactured batch is expected to be available, at the latest, by the fourth quarter of calendar 2020. In addition, the Company is also forecasting approximately \$1,755,000 for technology transfer to a new manufacturer in fiscal 2021.

The Company is currently forecasting to spend approximately \$1,400,000 in collaborative research initiatives with both ProMab and the Moffit Cancer Centre.

The Company's cash reserves of \$4,989,000 as at April 30, 2020 are insufficient to meet anticipated cash needs for working capital and capital expenditures through the next twelve months, nor are they sufficient to see planned research and development initiatives through to completion. Though the funds raised have assisted the Company in dealing with its working capital deficiency, additional funds are required to advance the Company's clinical and preclinical programs and deal with working capital requirements. To the extent that the Company does not believe it has sufficient liquidity to meet its current obligations, management considers securing additional funds, primarily through the issuance of equity securities of the Company, to be critical for its development needs.

The Company's long-term liquidity depends on its ability to raise funds from various sources, which depends substantially on the success of its ongoing research and development programs, economic conditions and the state of the biotech industry.

Accessing the capital markets can be particularly challenging for companies that operate in the biotechnology industry. While the Company has been able to raise equity financing in recent years, there can be no assurance that additional funding by way of equity financing will continue to be available. Any additional equity financing, if secured, would result in dilution to the existing shareholders and such dilution may be significant. The Company may also seek additional funding from or through other sources, including technology licensing, co-development collaborations, mergers and acquisitions, joint ventures, and other strategic alliances, which, if obtained, may reduce the Company's interest in its projects or products or result in significant dilution to existing shareholders. The Company may also seek additional funding from government grants. The Company is also assessing the possibility of a Nasdaq listing in order to reach the U.S. capital markets for funding. There can be no assurance, however, that any alternative sources of funding will be available. The failure of the Company to obtain additional financing on a timely basis may result in the Company reducing, delaying or cancelling one or more of its planned research, development and/or marketing programs, including clinical trials, further reducing overhead, or monetizing non-core assets, any of which could impair the current and future value of the business or cause the Company to consider ceasing operations and undergoing liquidation.

Given the Company's conclusion about the insufficiency of its cash reserves, significant doubt may be cast about the Company's ability to continue operating as a going concern. The continuation of the Company as a going concern for the foreseeable future depends mainly on raising sufficient capital, and in the interim, reducing, where possible, operating expenses (including making changes to the Company's research and development plans), including the delay of one or more of the Company's research and development programs, further reducing overhead and the possible disposition of assets.

The Company had a total number of 132,933,017 common shares issued and outstanding as at April 30, 2020 (July 31, 2019 – 111,225,501).

## RELATED PARTY TRANSACTIONS

The following table summarizes for key management personnel compensation for the three-month and nine-month periods ended:

	For the three-month periods ended April 30		For the nine-month periods ended April 30	
	2020	2019	2020	2019
Compensation	\$ 147,000	\$ 147,000	\$ 440,000	\$ 440,000
Stock-based compensation	–	–	107,000	–
	\$ 147,000	\$ 147,000	\$ 547,000	\$ 440,000

The following table summarizes non-management directors' compensation:

	For the three-month periods ended April 30		For the nine-month periods ended April 30	
	2020	2019	2020	2019
Director fees	\$ 40,000	\$ 42,000	\$ 120,000	\$ 122,000
Stock-based compensation	213,000	–	227,000	–
	\$ 253,000	\$ 42,000	\$ 347,000	\$ 122,000

The following table summarizes the both ACM Alpha Consulting Management EST ("ACMest") and ACM Alpha Consulting Management AG ("ACMag"):

	For the three-month periods ended April 30		For the nine-month periods ended April 30	
	2020	2019	2020	2019
Financial and investor relations consulting	\$ 139,000	\$ 128,000	\$ 405,000	\$ 386,000
Finder fee commissions	750,000	76,000	2,000,000	823,000
	\$ 889,000	\$ 204,000	\$2,405,000	\$ 1,209,000

The Company has agreements with both ACM Alpha Consulting Management EST ("ACMest") and ACM Alpha Consulting Management AG ("ACMag"). The agreements are both effective July 2, 2018 and can be terminated upon ninety days notice. Mr. Kandziora is President of ACMest and acted as Observer on the Board of Directors of the Company up until August 22, 2019 in addition to also being on the Supervisory Board of the Company's Polish subsidiary, Helix Immuno-Oncology S.A. Mrs. Kandziora is President of ACMest and was Corporate Secretary up until August 22, 2019.

Related party transactions are at arm's length and recorded at the amount agreed to by the related parties.

## FINANCIAL INSTRUMENTS

### *Fair value hierarchy*

Financial instruments recorded at fair value on the balance sheet are classified using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels:

- Level 1 reflects valuation based on quoted prices observed in active markets for identical assets or liabilities;
- Level 2 reflects valuation techniques based on inputs that are quoted prices of similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; inputs other than quoted prices used in a valuation model that are observable for that instrument; and inputs that are derived principally from or corroborated by observable market data by correlation or other means; and
- Level 3 reflects valuation techniques with significant unobservable market inputs.

A financial instrument is classified to the lowest level of the hierarchy for which a significant input has been considered in measuring fair value. The financial instrument in the Company's financial statements, measured at fair value, is cash.

### *Fair value*

The fair value of financial instruments as at April 30, 2020 and July 31, 2019 approximates their carrying value because of the near-term maturity of these instruments.

## **INTELLECTUAL PROPERTY**

Patents and other proprietary rights are very valuable to the Company, even though the patent positions of biotechnology companies may be uncertain and involve complex legal and factual issues. The Company has no assurance that any of its patent applications will result in the issuance of any patents. Even issued patents may not provide the Company with a competitive advantage against competitors with similar technologies, or who have designed around the Company's patents. Furthermore, the Company's patents may be struck down if challenged. Intellectual property laws do not protect intellectual property to the same extent from one country to another.

Because of the substantial length of time and expense associated with developing new products, the pharmaceutical, medical device, and biotechnology industries place considerable importance on obtaining patent protection for new technologies, products, and processes. The Company's policy is to file patent applications to protect inventions, technology, and improvements that are important to the development of our business and with respect to the application of our products and technologies to the treatment of a number of disease indications. The Company's policy also includes regular reviews related to the development of each technology and product in light of its intellectual property protection, with the goal of protecting all key research and developments by patent.

The Company seeks intellectual property protection in various jurisdictions around the world and owns patents and patent applications relating to products and technologies in the United States, Canada, Europe and other jurisdictions. The scope and duration of our intellectual property rights vary from country to country depending on the nature and extent of our intellectual property filings, the applicable statutory provisions governing the intellectual property, and the nature and extent of our legal rights. The Company will continue to seek intellectual property protection as appropriate and require our employees, consultants, outside scientific collaborators, and sponsored researchers to enter into confidentiality agreements with us that contain assignment of invention clauses outlining ownership of any intellectual property developed during the course of the individual's relationship with us.

### ***DOS47, L-DOS47 and V-DOS47***

The Company currently owns three U.S. patents in respect of the DOS47 technology, and also has also licensed patent rights from the NRC for the antibody component of L-DOS47. With respect to non-U.S. patents, the Company owns a number of DOS47 related patents in other jurisdictions with a number of patent applications in countries around the world. During January 2015, an additional U.S. patent application covering specific L-DOS47 manufacturing and novel features was filed. During fiscal 2017, a new U.S. patent application protecting the novel use of L-DOS47 in restoring T cell function for therapeutic application was filed. In addition, two US patents covering anti-VEGFR2 antibodies and their use in DOS47 conjugates (V-DOS4) were filed.

### ***Cell Based Therapy***

The company has recently filed a joint patent application with NRC to protect the use of an antibody for use in cell-based therapies. In addition, the company has also filed new patent application covering the use of anti-VEGFR2 antibodies in cell-based therapy in July 2017. The Company is currently in discussion with third parties to license additional intellectual properties to strengthen the company's portfolio.

## **OFF-BALANCE SHEET ARRANGEMENTS**

The Company has no material off-balance sheet arrangements.

## **SUBSEQUENT EVENT**

The Company announced on June 26, 2020 that it had entered into a non-binding term sheet to divest the remaining shares it holds in its Polish subsidiary, Helix Immuno-Oncology SA ("HIO"), representing approximately 51 per cent of the issued and outstanding shares of HIO as at April 30, 2020.

Under the term sheet, the Company has accepted a non-binding offer from CAIAC Fund Management AG, in its capacity as designated trustee of an alternative investment fund that is currently in the process of being established and authorized by the Financial Market Authority in Liechtenstein ("FMA"). The terms of the offer provide for the Company to sell its remaining holdings in HIO for gross proceeds of 6.7 million Polish zloty (approximately \$2.3 million). The transaction is scheduled to close on Aug. 31, 2020, and is subject to a number of conditions, including the approval of the fund by the FMA; the raising of a minimum 7.3 million Polish zloty by the fund as well as regulatory approval of the transaction, if required. There can be no assurance that the closing of the divestment will occur on the terms set out herein or at all.

The Company has also approved an increase in share capital of HIO and the issuance of up to 2.2 million Series B ordinary shares in the capital of HIO to enable it to issue up to 2.2 million Series B ordinary shares by way of a private placement financing for aggregate gross proceeds of approximately 2.97 million Polish zloty. HIO completed the private placement on July 8, 2020 and as a result the Company's shareholding in HIO has been reduced to approximately 42.5% of the outstanding shares of HIO.

In addition, the Company has entered into agreements with HIO, pursuant to which it has cancelled an aggregate amount of approximately \$2.7 million of intercompany debt owed to the Company by HIO. Since HIO is a subsidiary of the Company, the consolidated statements of financial position of the Company have not presented intercompany transactions. As part of the debt cancellation agreements, the Company and HIO have agreed to terminate both the Biphasix asset transfer agreement and the V-DOS47 license agreement. As a result, all transferred assets related to Biphasix and V-DOS47 have been automatically reassigned and transferred from HIO back to the Company without any formality. The Company has also ceased financing HIO with immediate effect.

## TABULAR DISCLOSURE OF CONTRACTUAL OBLIGATIONS

The Company's fiscal year commitments are summarized as follows:

	2020	2021	2022	2023	2024	2025 and beyond	Total
Clinical research organizations <sup>(1)</sup>	\$ 466,000	\$ 2,162,000	\$ 1,083,000	\$ 106,000	\$ –	\$ –	\$ 3,817,000
Contract manufacturing organizations <sup>(2)</sup>	128,000	723,000	–	–	–	–	851,000
Collaborative research organizations <sup>(3)</sup>	–	904,000	–	–	–	–	904,000
Royalty and in-licensing <sup>(4)</sup>	–	20,000	20,000	20,000	20,000	80,000	160,000
Financial & investor relations <sup>(5)</sup>	142,000	–	–	–	–	–	142,000
Facility leases <sup>(6)</sup>	27,000	–	–	–	–	–	27,000
	\$ 763,000	\$ 3,809,000	\$ 1,103,000	\$ 126,000	\$ 20,000	\$ 80,000	\$ 5,901,000

- (1) The Company has Clinical Research Organization supplier agreements in place for clinical research services and passthrough costs related to the Company's clinical stage programs.
- (2) The Company has Contract Manufacturing Organization supplier agreements related to its L-DOS47 program, all of which are inter-dependant with the manufacturing of L-DOS47.
- (3) The Company has Collaborative Research Organization agreements relating to its L-DOS47 program.
- (4) Represents future minimum royalties.
- (5) The Company amended a financial advisory agreement dated July 2, 2018 which includes a termination clause which requires a ninety-day written notice (also see *RELATED PARTY TRANSACTIONS* section above).
- (6) The Company is committed to pay \$27,000 under three facility lease agreements.

## QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The Company's main objectives when managing capital are to ensure sufficient liquidity to finance research and development activities, clinical trials, ongoing administrative costs, working capital and capital expenditures. The Company includes cash and components of shareholders' equity, in the definition of capital. The Company endeavours not to unnecessarily dilute shareholders when managing the liquidity of its capital structure.

### Currency risk

The Company operates internationally and is exposed to foreign exchange risks from various currencies, primarily the Euro and U.S. dollar. Foreign exchange risks arise from the foreign currency translation of the Company's integrated foreign operation in Poland. In addition, foreign exchange risks arise from purchase transactions, as well as recognized financial assets and liabilities denominated in foreign currencies.

Balances in foreign currencies at:

	April 30, 2020			July 31, 2019		
	Euros	US Dollars	Zloty	Euros	US Dollars	Zloty
Cash	–	–	63,000	–	–	330,000
Accounts receivable	–	–	57,000	–	–	143,000
Accounts payable	(247,000)	(235,000)	(83,000)	(401,000)	(563,000)	(232,000)
Accruals	–	(158,000)	(88,000)	(25,000)	–	(107,000)
Net foreign currencies	(247,000)	(393,000)	(51,000)	(426,000)	(563,000)	(134,000)
Closing exchange rate	1.5186	1.3910	0.3325	1.4627	1.3148	0.3413
Impact of 1% change in exchange rate	+/- 4,000	+/- 5,000	+/- nil	+/- 6,000	+/- 7,000	+/- nil

Any fluctuation in the exchange rates of the foreign currencies listed above could have an impact on the Company's results from operations; however, they would not impair or enhance the ability of the Company to pay its foreign-denominated expenses.

### **Credit risk**

Credit risk is the risk of a financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligation.

The table below breaks down the various categories that make up the Company's accounts receivable balances as at:

	April 30, 2020	July 31, 2019
Government related – HST/VAT	\$ 80,000	\$ 82,000
Research and development investment tax credits	115,000	121,000
Other	1,000	87,000
	\$ 196,000	\$ 290,000

### **Interest rate risk**

Interest rate risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in interest rates, which are affected by market conditions. The Company is exposed to interest rate risk arising from fluctuations in interest rates received on its cash. The Company does not have any credit facilities and is therefore not subject to any debt related interest rate risk.

The Company manages its interest rate risk by maximizing the interest income earned on excess funds while maintaining the liquidity necessary to conduct its operations on a day-to-day basis. Any investment of excess funds is limited to risk-free financial instruments. Fluctuations in the market rates of interest do not have a significant impact on the Company's results of operations due to the relatively short-term maturity of any investments held by the Company at any given point in time and the low global interest rate environment. The Company does not use derivative instruments to reduce its exposure to interest rate risk.

### **Liquidity risk**

Liquidity risk is the risk that the Company will not be able to meet its obligations as they come due.

Since inception, the Company has mainly relied on financing its operations from public and private sales of equity. The Company does not have any credit facilities and is therefore not subject to any externally imposed capital requirements or covenants.

The Company manages its liquidity risk by continuously monitoring forecasts and actual cash flow from operations and anticipated investing and financing activities.

The Company's cash reserves of \$4,989,000 as at April 30, 2020 are insufficient to meet anticipated cash needs for working capital and capital expenditures through the next twelve months, nor are they sufficient to see the current research and development initiatives through to completion. To the extent that the Company does not believe it has sufficient liquidity to meet its current obligations, management considers securing additional funds primarily through equity arrangements to be of utmost importance.

The Company's long-term liquidity depends on its ability to access the capital markets, which depends substantially on the success of the Company's ongoing research and development programs, as well as economic conditions relating to the state of the capital markets generally. Accessing the capital markets is particularly challenging for companies that operate in the biotechnology industry.

The following are the contractual maturities of the undiscounted cash flows of financial liabilities as at:

	April 30, 2020			July 31, 2019		
	Carrying amount	Less than one year	Greater than one-year	Carrying amount	Less than one year	Greater than one-year
Accounts payable	\$ 1,090,000	\$ 1,090,000	\$ –	\$ 3,040,000	\$ 3,040,000	\$ –
Accrued liabilities	471,000	471,000	–	1,057,000	1,057,000	–

This table only covers liabilities and obligations relative to financial instruments and does not anticipate any income associated with assets nor does it include liabilities related to assets held for sale.

### **OUTSTANDING SHARE DATA**

As at April 30, 2020, the Company had outstanding 132,933,017 common shares; warrants to purchase up to 65,080,413 common shares; and incentive stock options to purchase up to 5,225,000 common shares. As at July 31, 2019, the Company had outstanding 111,225,501 common shares; warrants to purchase up to 43,372,897 common shares; and incentive stock options to purchase up to 4,875,000 common shares.

## DISCLOSURE CONTROLS AND PROCEDURES AND INTERNAL CONTROL OVER FINANCIAL REPORTING

Management has designed the Company's disclosure controls and procedures to provide reasonable assurance that all relevant information is gathered, recorded, summarized and reported to the Chief Executive Officer ("CEO") and the Chief Financial Officer ("CFO") of the Company so that appropriate decisions can be made within the time periods specified in securities legislation regarding public disclosure by the Company in its annual filings, interim filings or other documents or reports required to be filed or submitted by it under securities legislation.

Management has also designed internal controls over financial reporting ("ICFR") to provide reasonable assurance regarding the reliability of the Company's financial reporting and the preparation of financial statements for external purposes in accordance with IFRS. Because of its inherent limitations, ICFR can provide only reasonable assurance and may not prevent or detect misstatements. Further, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with policies or procedures may deteriorate.

### ***Material weakness previously disclosed but not yet remediated***

The termination of the Company's controller in fiscal 2017, whose position to this day has not been filled, resulted in a lack of resources and has in turn impacted segregation of duties associated with the financial close and reporting process.

As at April 30, 2020, management has evaluated the effectiveness of the Company's disclosure controls and procedures and ICFR and have concluded they are not effective due to the above noted area of concern.

Management has concluded and the board has agreed, that when taking into account the Company's size and financial resources, the Company does not have sufficient scale of resources to warrant the hiring of additional staff to address this concern at this time and, accordingly, that there is a material weakness in the design of the Company's ICFR that has the potential to result in material misstatements in the Company's financial statements and that this should also be considered a weakness in the design and operating effectiveness of the Company's disclosure controls and procedures. This material weakness is considered to be a common area of deficiency for many smaller listed companies in Canada.

Although the CEO and CFO are not aware of the above deficiency having actually resulted in a material misstatement of a financial statement amount or disclosure, they have determined that, the deficiency could result in business and accounting practices that could put both the Company's reputation and its financial reporting at risk and lead to uncertainty whether control procedures are being carried out such that the Company's ICFR may fail to prevent or detect a material misstatement of a financial statement amount or disclosure on a timely basis or fail to disclose material information required to be disclosed under securities legislation within the time periods specified in securities legislation. However, there are several mitigating procedures and other factors which reduce the risk of a material misstatement in the financial statements, including substantive review of the financial statements by the Company's audit committee and day-to-day management involvement in operations and reporting.

## RISKS AND UNCERTAINTIES

Helix is subject to risks, events and uncertainties, or "risk factors", associated with being a publicly traded company operating in the biotechnology industry, with research and development stage projects in pre-clinical discovery and clinical development and with no expectation of revenue or profits in the foreseeable future and, as such, is heavily dependant on raising sufficient capital on a timely bases in order to advance the Company's drug development programs. As a result of these risk factors, reported information and forward-looking information may not necessarily be indicative of future operating results or of future financial position, and actual results may vary from the forward-looking information or reported information. The Company cannot predict all of the risk factors, nor can it assess the impact, if any, of such risk factors on the Company's business or the extent to which any factor, or combination of factors, may cause future results or financial position to differ materially from either those reported or those projected in any forward-looking information. Accordingly, reported financial information and forward-looking information should not be relied upon as a prediction of future actual results. Some of the risks and uncertainties affecting the Company, its business, operations and results which could cause actual results to differ materially from those reported or from forward-looking information include, either wholly or in part, those described elsewhere in this MD&A, as well as the following:

### ***The Company does not have any source of operating income and is dependent solely on outside sources of financing***

The Company's operations consist of research and development activities, which do not generate any revenue. Accordingly, the Company has no source of revenue, positive operating cash flow or operating earnings to subsidize its ongoing research and development and other operating activities and the ability of the Company to continue as a going concern is dependent upon the Company's ability to rely on cash on hand, and on outside sources of financing to fund its ongoing research and development and other operating activities. Such sources of financing involve risks, including that the Company will not be able to raise such financing on terms satisfactory to the Company or at all, and that any additional equity and/or any convertible debt financing, if secured, would result in dilution to existing shareholders, and that such dilution may be significant. While the Company has been able to raise equity financing in recent years, there can be no assurance that additional funding by way of equity financing will continue to be available. Any additional equity

and/or debt financing, if secured, would result in dilution to the existing shareholders and such dilution may be significant. The Company may also seek additional funding from or through other sources, including technology licensing, co-development collaborations, mergers and acquisitions, joint ventures, and other strategic alliances, which, if obtained, may reduce the Company's interest in its projects or products or result in significant dilution to existing shareholders. The Company may also seek additional funding from government grants. There can be no assurance, however, that any alternative sources of funding will be available. The failure of the Company to obtain additional financing on a timely basis may result in the Company reducing, delaying or cancelling one or more of its planned research and development programs, including clinical trials, further reducing overhead, or monetizing non-core assets, any of which could impair the current and future value of the business or cause the Company to consider ceasing operations and undergoing liquidation. Given the Company's conclusion about the insufficiency of its cash reserves, significant doubt may be cast about the Company's ability to continue operating as a going concern. The continuation of the Company as a going concern for the foreseeable future depends mainly on raising sufficient capital, and in the interim, reducing, where possible, operating expenses (including making changes to the Company's research and development plans), including the delay of one or more of the Company's research and development programs, further reducing overhead and the possible disposition of assets.

***The Company has a history of losses and expects to continue to incur additional losses for the foreseeable future***

The Company's primary focus continues to be on its research and development of drug product candidates. The research and development of drug product candidates require the expenditure of significant amounts of cash over a relatively long-time period. The Company expects to continue to incur losses from continuing operations, for the foreseeable future. The Company's cumulative deficit as at April 30, 2020 is \$178,427,000. There can be no assurance that the Company will record earnings in the future.

***The Company requires additional funding***

The Company's cash reserves will not be sufficient for the Company to fully fund the Company's ongoing research and development programs, operating activities, working capital or capital expenditures for the next twelve months. The Company has no sources of external liquidity, such as a bank loan or line of credit. The Company is therefore in need of additional equity and/or debt financings in order to fund its ongoing research and development programs and other operating expenses for the foreseeable future.

The failure of the Company to obtain additional financing on a timely basis may result in the Company reducing, delaying or cancelling one or more of its planned research and development, including any clinical trials, further reducing overhead, or monetizing non-core assets, any of which could impair the current and future value of the business or cause the Company to consider ceasing operations and undergoing liquidation.

***The Company faces risks in connection with competition and technological change;***

The biotechnology industry is subject to rapid and substantial technological change. Technological competition from pharmaceutical companies, biotechnology companies and university researchers is intense and is expected to continue to be intense.

The rapid advancement of immunotherapies has and likely will continue to significantly change the treatment of cancer and may result in a reduction, which may be significant, in the potential patient population and/or treatment protocols available to chemotherapies and other treatments currently in development, such as the Company's primary drug product candidate, L-DOS47. Developments in immunotherapies have resulted in the Company repositioning its L-DOS47 lead drug product candidate away from a front-line monotherapy protocol towards second and third-line combination therapies with existing chemotherapy drugs and possibly in combination with immunotherapies resulting in additional expenditures and delays in previously anticipated development timelines for L-DOS47. Advancements in technology can impact the Company at any time and as such, any further repositioning, would likely result in additional expenses being incurred by the Company and in further delays in the anticipated development timeline for L-DOS47, or in the Company determining that its L-DOS47 drug product candidate is no longer viable. The Company is currently heavily dependent on the success of its lead drug product candidate L-DOS47 which is the only drug candidate currently in clinical development.

The Company cell-based therapies initiative may face significant hurdles. The Company's effort is mainly at research proof-of-concept stage. It is possible that the selected targets or choice of antibodies are not optimal. This can delay the initiation of formal preclinical and clinical development significantly. The Company has chosen to develop cell-based therapy for solid tumour. While there are many successful examples of cell-based therapy treatment in hematological malignancies, similar success in solid tumour is less certain.

Many of the Company's competitors have substantially greater financial, technical and human resources and significantly greater experience in conducting preclinical testing and human clinical trials of product candidates, scaling up manufacturing operations and obtaining regulatory approvals of products. Accordingly, the Company's varying competitors

may succeed in obtaining regulatory approval for products more rapidly. The Company's ability to compete successfully will largely depend on:

- the efficacy and safety profile of our product candidates relative to marketed products and other product candidates in development;
- our ability to develop and maintain a competitive position in the product categories and technologies on which we focus;
- the time it takes for our product candidates to complete clinical development and receive marketing approval;
- our ability to obtain required regulatory approvals;
- our ability to commercialize any of our product candidates that receive regulatory approval;
- our ability to establish, maintain and protect intellectual property rights related to our product candidates; and
- acceptance of any of our product candidates that receive regulatory approval by physicians and other healthcare providers and payers.

Competitors have developed and may develop technologies that could be the basis for products that challenge the differentiated nature and potential for best-in-class product development programs and discovery research capabilities of the DOS47 platform technology. Some of those products may have an entirely different approach or means of accomplishing the desired therapeutic effect than our product candidates and may be more effective or less costly than our product candidates. The success of our competitors and their products and technologies relative to our technological capabilities and competitiveness could have a material adverse effect on the future preclinical studies and clinical trials of our product candidates, including our ability to obtain the necessary regulatory approvals for the conduct of such clinical trials. This may further negatively impact our ability to generate future product development programs with improved pharmacological properties.

With the recent FDA approval of pembrolizumab (Keytruda®) as first line treatment for NSCLC with PD-L1>1%, either as first line or in combination with carboplatin/pemetrexed, there is an urgent need for data to demonstrate the safety of L-DOS47 in combination with accepted standard chemotherapies, and also in combination with immunotherapies that are being offered with growing frequency. In addition, the rapidly evolving treatment landscape and growing prominence of immunotherapies, along with the infrequent use of vinorebine/cisplatin chemotherapy combination in the U.S., the potential relevance of data from the Company's LDOS003 study may be limited.

If we are not able to compete effectively against our current and future competitors, our business will not grow and our financial condition and operations will substantially suffer.

***The Company is conducting early stage research and development initiatives for products under development which may not be accepted by the market and may never generate revenue and the Company has limited sales, marketing and distribution experience***

The Company is conducting early stage research and development initiatives and is currently in the process of developing new products that require further time consuming and costly research and development. It will be a number of years, if ever, before its products in development begin to generate revenues, if at all. There can be no assurance that any of the drug product candidates will ever be successfully developed or commercialized.

Even with regulatory approval, the Company may not achieve market acceptance, which depends on a number of factors, including the establishment and demonstration in the medical community of the clinical utility of the Company's products, and their potential advantage over alternative treatment methods. There is also the risk that the actual market size or opportunity for the Company's drug candidates is not certain. Failure to gain market acceptance of either of the Company's products currently under development or an incorrect estimate in the nature and size of their respective markets could have a material adverse effect on the Company.

The Company has limited sales, marketing and distribution experience, and there is no assurance that the Company will be able to establish adequate sales, marketing, and distribution capabilities or make arrangements with any collaborators, strategic partners, licensees, or others to perform such activities, or that such efforts will be successful. The Company's objective for its drug candidate products is to enter into strategic alliances with appropriate pharmaceutical partners. There can be no assurance that any such strategic alliance will be maintained or achieved, or if achieved, that it will result in revenue to the Company.

***The timing of the Company's internal goals and projected timelines may not be met***

The Company sets internal goals for and makes public statements regarding its expected timing of meeting the objectives material to its success, including the commencement, duration and completion of clinical trials and anticipated regulatory approvals. The actual timing of these forward-looking events can vary dramatically due to a number of factors, including, without limitation, delays in scaling-up of drug product candidates, delays or failures in clinical trials, additional data requirements from the regulators, the Company failing to obtain required financing, and other risks referred to herein. Without limiting the generality of the foregoing, it is possible that required regulatory approvals may be delayed or denied,

including those related to undertaking or continuing clinical trials, manufacturing of drug products, and marketing such products.

The Company has expressed certain estimated timelines for its European Phase I/II clinical trials for L-DOS47 in Poland, the U.S. Phase I study. The timeline for the European Phase I/II trials and any future timelines are contingent on the Company having adequate financing to complete the trials and the assumption that the trials will be completed according to the current schedules. A failure to obtain necessary financing or a change in the schedule of the trials (which may occur if certain cost-deferral measures are taken, or due to factors beyond the Company's reasonable control, such as scheduling conflicts, the occurrence of serious adverse events, interruption of supplies of study drugs, withdrawals of regulatory approvals, or slow patient recruitment) could delay their commencement or completion, or result in their suspension or early termination, which could have a material adverse effect on the Company.

***The Company faces intellectual property risks, including the loss of patent protection, the potential termination of licences, the inability to protect proprietary property, and possible claims of infringement against the Company or against a third-party from whom the Company licenses intellectual property***

The Company's success depends, in part, on its ability to secure and protect its intellectual property rights and to operate without infringing on the proprietary rights of others or having third parties circumvent the rights owned or licensed by the Company. However, the Company cannot predict the enforceability of its patents or its ability to maintain trade secrets that may not be protected by patents. Patent risks include the fact that patent applications may not result in issued patents, issued patents may be circumvented, challenged, invalidated or insufficiently broad to protect the Company's products and technologies; blocking patents by third parties could prevent the Company from using its patented technology; it may be difficult to enforce patent rights, particularly in countries that do not have adequate legal enforcement mechanisms, and enforcing such rights may divert management attention and may cause the Company to incur significant expenses; and any expiry of an issued patent may negatively impact the underlying technology.

To protect its trade secrets, the Company enters into confidentiality undertakings with parties that have access to them, such as the Company's current and prospective distributors, collaborators, employees and consultants, but a party may breach the undertakings and disclose the Company's confidential information or competitors might learn of the information in some other way, which could have a material adverse effect on the Company.

The Company uses processes, technology, products, or information, the rights to certain of which are owned by others, such as a license from the NRC of the lung antibody used by the Company for L-DOS47. Termination or expiry of any licenses or rights during critical periods, and an inability to obtain them on commercially favourable terms or at all could have a material adverse effect on the Company and its drug candidates' development.

The Company operates in an industry that experiences substantial litigation involving the manufacture, use and sale of new products that are the subject of conflicting proprietary rights. The Company or one or more of its licensors may be subject to a claim of infringement of proprietary rights by a third party. It is possible that the Company's products and technologies do infringe the rights of third parties, and the Company or such licensor could incur significant expenses, and diversion of management attention, in defending allegations of infringement of proprietary rights, even if there is no infringement. Furthermore, the Company or such licensors may be required to modify its products or obtain licenses for intellectual property rights as a result of any alleged proprietary infringement. The inability to modify products or obtain licenses on commercially reasonable terms, in a timely manner or at all, could adversely affect the Company's business.

***The Company faces research and development risks, including the need to prove the Company's drug candidates are safe and effective in clinical trials***

The Company's drug candidates are complex compounds and the Company faces difficult challenges in connection with the manufacture of clinical batches of each of them, which could further delay or otherwise negatively affect the Company's planned clinical trials, or required regulatory approvals.

There is also the risk that the Company could obtain negative findings or factors that may become apparent during the course of research or development. The results from preclinical and clinical trials may not be predictive of results obtained in any ongoing or future clinical trials. A number of companies in the biotechnology and pharmaceutical industry have suffered significant setbacks in advanced clinical trials, even after achieving promising results in earlier trials and pre-clinical trials.

The timing and success of the Company's clinical trials also depend on a number of other factors, including, but not limited to: (a) obtaining additional financing, which is not assured; (b) sufficient patient enrolment, which may be affected by the incidence of the disease studied, the size of the patient population, the nature of the protocol, the proximity of patients to clinical sites, the eligibility criteria for a patient to participate in the study and the rate of patient drop-out; (c) regulatory agency policies regarding requirements for approval of a drug, including granting permission to undertake proposed human testing; (d) the Company's capacity to produce sufficient quantities and qualities of clinical trial materials

to meet the trial schedule; (e) performance by third parties, on whom the Company relies to carry out its clinical trials; and (f) the approval of protocols and/or protocol amendments.

Clinical trials are complex, expensive and uncertain, and have a high risk of failure, which can occur at any stage. Data obtained from pre-clinical and clinical trials may be interpreted in different ways, or be incorrectly reported, which could delay or prevent further development of the drug candidate studied. Failure to complete clinical trials successfully and to obtain successful results on a timely basis could have a material adverse effect on the Company.

Even if the Company's drug candidates successfully complete the clinical trials and receive the regulatory approval necessary to market the drug candidates to the public, there is also the risk of unknown side effects, which may not appear until the drug candidates are on the market and may result in delay or denial of regulatory approval or withdrawal of previous approvals, product recalls or other adverse events, which could materially adversely affect the Company.

While the Company continues to explore opportunities to expand its drug product pipeline with new DOS47-based therapeutics pending the identification of further tumour targeting agents, there can be no assurance that any such tumour targeting agents will be identified or that any new DOS47-based therapeutics will be developed.

***Difficulty in enrolling patients in the Company's clinical trials, could result in delays or cancellation of clinical trials***

As the Company's product candidates advance from preclinical testing to clinical testing, and then through progressively larger and more complex clinical trials, the Company will need to enroll an increasing number of patients that meet various eligibility criteria. There is significant competition for recruiting cancer patients in clinical trials, and the Company may be unable to enroll the patients it needs to complete clinical trials on a timely basis or at all. The factors that affect the Company's ability to enroll patients is largely uncontrollable and include, but are not limited to, the following:

- size and nature of the patient population;
- eligibility and exclusion criteria for the trial;
- design of the study protocol;
- competition with other companies for clinical sites or patients;
- the perceived risks and benefits of the product candidate under study;
- the patient referral practices of physicians; and
- the number, availability, location and accessibility of clinical trial sites.

***The Company is dependent on a number of third parties and the failure or delay in the performance of one of these third parties' obligations may adversely affect the Company***

The Company is dependent on third parties to varying degrees in virtually all aspects of its business, including without limitation, on contract research organizations, contract manufacturing organizations, clinical trial consultants, raw material suppliers, collaborative research consultants, regulatory affairs advisers, medical and scientific advisors, clinical trial investigators, business service providers and other third parties. Critical supplies may not be available from third parties on acceptable terms, or at all, including GMP grade materials. Service providers may not perform, or continue to perform, as needed, or be available to provide the required services on acceptable terms or at all. Any lack of or interruption in supplies of raw materials or services, or any change in supply or service providers or any inability to secure new supply or service providers, would have an adverse impact on the development and commercialization of the Company's products. For example, the Company has previously experienced delays in the manufacturing of both engineering and clinical batches of L-DOS47, which have in turn caused delays in the progression of its development program, and there may be further delays. The Company relies on a third party for its supply of urease and if the contract with the third-party urease supplier is terminated early, the Company will have to find a new supplier of urease, as well as a new manufacturer of bulk drug product for future clinical testing programs. There can be no assurance that a new supplier or manufacturer can be contracted in a timely manner or at all, and this could negatively impact the Company's development plans for L-DOS47.

With respect to L-DOS47, the Company is currently dependent on, in addition to third party suppliers, manufacturers and consultants, the NRC and its license to the Company of a lung cancer antibody in order to develop and commercialize L-DOS47. Early termination of the license with NRC would have a material adverse effect on the further development of L-DOS47 and may require the cessation of such development, which would have a material adverse effect on the Company.

Given the Company's lack of financing, expertise, infrastructure and other resources to support a new drug product from clinical development to marketing, the Company also requires strategic partner support to develop and commercialize its drug candidates. There can be no assurance that such strategic partner support will be obtained upon acceptable terms or at all.

The Company relies heavily on contract manufacturers for the production of product required for its clinical trials, product formulation work, scaling-up experiments and commercial production. The Company may not be able to obtain new, or

keep its current, contract manufacturers to provide these services. Even if the Company does, contract manufacturers may not be reliable in meeting its requirements for cost, quality, quantity or schedule, or the requirements of any regulatory agencies. The Company may not be able to manufacture products in quantities or qualities that would enable the Company to meet its business objectives, and failure to do so would materially adversely affect the Company's business.

If the Company can successfully develop markets for its products, the Company would have to arrange for their scaled-up manufacture. There can be no assurance that the Company will, on a timely basis, be able to make the transition from manufacturing clinical trial quantities to commercial production quantities successfully or be able to arrange for scaled-up commercial contract manufacturing. Any potential difficulties experienced by the Company in manufacturing scale-up, including recalls or safety alerts, could have a material adverse effect on the Company's business, financial condition, and results of operations.

***The marketability of the Company's products may be affected by delays and the inability to obtain necessary approvals, and following any market approval, the Company's products will be subject to ongoing regulatory review and requirements which may continue to affect their marketability, including but not limited to regulatory review of drug pricing, healthcare reforms or the payment and reimbursement policies for drugs by the various insurers and other payors in the industry***

The research, development, manufacture and marketing of pharmaceutical products are subject to regulation by the FDA, and comparable regulatory authorities in other countries. These agencies and others regulate the testing, manufacture, safety and promotion of the Company's products. The Company must receive applicable regulatory approval of a product candidate before it can be commercialized in any particular jurisdiction. Approval by a regulatory authority of one country does not ensure the approval by regulatory authorities of other countries. Changes in regulatory approval policies or regulations during the development period may cause delays in the approval or rejection of an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application, or may decide that our data are insufficient for approval, or require additional preclinical, clinical or other trials and place the Company's IND submissions on hold for an indeterminate amount of time. The development and regulatory approval process in each jurisdiction takes many years, requires the expenditure of substantial resources, is uncertain and subject to delays, and can adversely affect the successful development and commercialization of our drug candidates.

Even if the Company obtains marketing approval in a particular jurisdiction, there may be limits on the approval and the Company's products likely will be subject to ongoing regulatory review and regulatory requirements in that jurisdiction. Pharmaceutical companies are subject to various government regulations, including without limitation, requirements regarding occupational safety, laboratory practices, environmental protection and hazardous substance control, and may be subject to other present and future regulations.

The availability of reimbursement by governmental and other third-party payors, such as private insurance plans, will affect the market for any pharmaceutical product, and such payors tend to continually attempt to contain or reduce the costs of healthcare. Significant uncertainty exists with respect to the reimbursement status of newly approved healthcare products.

***The Company operates in an industry that is more susceptible than others to legal proceedings and, in particular, liability claims***

The Company operates in an industry that is more susceptible to legal proceedings than firms in other industries, due to the uncertainty involved in the development of pharmaceuticals. Defense and prosecution of legal claims can be expensive and time consuming and may adversely affect the Company regardless of the outcome due to the diversion of financial, management and other resources away from the Company's primary operations. Negative judgments against the Company, even if the Company is planning to appeal such a decision, or even a settlement in a case, could negatively affect the cash reserves of the Company, and could have a material negative effect on the development of its drug products.

The Company may be exposed, in particular, to liability claims which are uninsured or not sufficiently insured, and any claims may adversely affect the Company's ability to obtain insurance in the future or result in negative publicity regarding the efficacy of its drug products. Such liability insurance is expensive, its ability is limited, and it may not be available on terms that are acceptable to the Company, if at all.

The use of any of the Company's unapproved products under development, the use of its products in clinical trials, and, if regulatory approval is received, the sale of such products, may expose the Company to liability claims which could materially adversely affect the Company's business. The Company may not be able to maintain or obtain commercially reasonable liability insurance for future products, and any claims under any insurance policies may adversely affect its ability to maintain existing policies or to obtain new insurance on existing or future products. Even with adequate insurance coverage, publicity associated with any such claim could adversely affect public opinion regarding the safety

or efficacy of the Company's products. As a result, any product liability claims or recall, including in connection with products previously sold by the Company through its former distribution business, could materially adversely affect the Company's business.

***If the Company were unable to maintain product liability insurance required by our third parties, the corresponding agreements would be subject to termination, which could have a material adverse impact on our operations.***

Some of our licensing and other agreements with third parties require or might require us to maintain product liability insurance. If the Company cannot maintain acceptable amounts of coverage on commercially reasonable terms in accordance with the terms set forth in these agreements, the corresponding agreements would be subject to termination, which could have a material adverse impact on the Company's operations.

***The Company is dependent upon key personnel; Director residency requirements***

The Company's ability to continue its development of potential products depends on its ability to attract and maintain qualified key individuals to serve in management and on the Board. However, the Company does not currently have a formal succession plan for members of its senior management team or for its Board and, because competition for qualified key individuals with experience relevant to the industry in which the Company operates is intense, the Company may not be able to attract and/or retain such personnel. Additionally, applicable corporate law requires that at least 25% of the Company's directors be resident Canadians, and the Company's articles provide that the Company cannot have fewer than five directors at any time.

Consequently, if the Company is unable to attract and/or loses and is unable to replace key personnel, its business could be negatively affected and, in particular, if the Company loses one or more of its three current resident Canadian directors in the future and is unable to find a sufficient number of resident Canadian directors to fill the resulting vacancy(ies), the Board will be prevented from taking any action other than appointing additional resident Canadian directors until such time as a sufficient number of new resident Canadian directors have been appointed such that at least 25% of the Company's directors are resident Canadians.

The Company employs a small number of employees who have many years of technical knowledge of the Company's technology and two senior officers, the CEO and CFO. The Novel Coronavirus ("COVID-19") imposes a high risk to all the Companies activities. The Company has established a policy to diligently monitor developments. Because the situation is fluid, the Company will be updating its staff whenever necessary. The Company has implemented and communicated a policy to all staff in order mitigate any potential risk.

In addition, the Company does not carry key-man insurance on any individuals.

***The Company's employees and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements, which could have a material adverse effect on the Company's business.***

The Company is exposed to the risk of employee and consultant fraud or other misconduct. Misconduct by employees and consultants could include, but are not limited to the following: failure to comply with regulators, failure to provide accurate information, failure to comply with manufacturing standards the Company has established, jurisdictional healthcare fraud and abuse of laws and regulations, failure to report financial information or data accurately or disclose unauthorized activities. For example, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing, and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee and consultant misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to the Company's reputation. If any such actions are instituted against the Company, and the Company is not successful in defending itself or asserting its rights, those actions could have a substantial impact on the Company's business and operating results, including the imposition of substantial fines, halt in trading of the Company's common shares, possible delisting and/or other sanctions.

***Indemnification obligations to directors and officers of the Company may adversely affect the Company's finances***

The Company has entered into agreements pursuant to which the Company has agreed to indemnify its directors and senior management in respect of certain claims made against them while acting in their capacity as such. If the Company is called upon to perform its indemnity obligations, its finances may be adversely affected.

***The Company's finances may fluctuate based on foreign currency exchange rates***

The Company operates internationally and is exposed to foreign exchange risks from various currencies, primarily the U.S. dollar, the Euro and the Polish Zloty.

### ***Unanticipated changes in the Company's tax rates could affect its future results***

Since the Company operates in different countries and is subject to taxation in different jurisdictions, its future effective tax rates could be impacted by changes in such countries' tax laws or their interpretations. Both domestic and international tax laws are subject to change as a result of changes in fiscal policy, changes in legislation, evolution of regulation and court rulings. The application of these tax laws and related regulations is subject to legal and factual interpretation, judgment and uncertainty.

### ***Shareholders of the Company may face dilution through exercise of stock options, warrants and future equity financings***

To attract and retain key personnel, the Company has granted options to its key employees, directors and consultants to purchase common shares and share awards as non-cash incentives. In addition, the Company has a significant number of warrants to purchase common shares outstanding. The issuance of shares pursuant to share awards and the exercise of a significant number of such options and warrants may result in significant dilution of other shareholders of the Company.

As noted above, the Company needs additional funding and has historically turned to the equity markets to raise this funding. The future sale of equity and warrants may also result in significant dilution to the shareholders of the Company.

### ***The Company's share price and trading volumes are volatile, and the Company may have difficulty maintaining listing requirements***

The price of the Company's common shares, as well as market prices for securities of biopharmaceutical and drug delivery companies generally, have historically been highly volatile, and have from time to time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies.

The trading price of the Company's common shares is subject to change and could in the future fluctuate significantly. The fluctuations could be in response to numerous factors beyond the Company's control, including: quarterly variations in results of operations; announcements of technological innovations or new products by the Company, its customers or competitors; changes in securities analysts' recommendations; announcements of acquisitions; changes in earnings estimates made by independent analysts; general fluctuations in the stock market; or revenue and results of operations below the expectations of public market securities analysts or investors. Any of these could result in a sharp decline in the market price of the common shares.

The Internet offers various avenues for the dissemination of information. The Company has no control over the information that is distributed and discussed on electronic bulletin boards and investment chat rooms. The intention of the people or organizations that distribute such information may not be in the Company's best interest and the best interests of its shareholders. This, in addition to other forms of investment information including newsletters and research publications, could result in a sharp decline in the market price of the common shares.

In addition, stock markets have occasionally experienced extreme price and volume fluctuations. The market prices for high-technology companies have been particularly affected by these market fluctuations and such effects have often been unrelated to the operating performance of such companies. These broad market fluctuations may cause a decline in the market price of the common shares.

Sales of substantial numbers of the Company's common shares could cause a decline in the market price of such common shares. There are minimum listing requirements for an issuer to maintain its listing on the Toronto Stock Exchange ("TSX"), and if the Company fails to maintain these listing requirements, it may be involuntarily delisted from the TSX. De-listing the Company or the Company shares from any securities exchange could have a negative effect on the liquidity of the Company shares and/or the ability of a shareholder to trade in shares of the Company, and could have an adverse effect on the Company's ability to raise future equity financings. The Company's common shares trade in a very low volume compared to the number of common shares outstanding. This means a shareholder could have difficulty disposing of common shares, especially if there are other shareholders of the Company trying to sell their shares in the Company at the same time. Volatility in share price and trading volumes could have an adverse effect on the Company's ability to raise future equity financings.

### ***The requirements of being a public company may strain the Company's resources, divert management's attention and affect its ability to attract and retain qualified board members***

As a public company, the Company is subject to the reporting requirements of Canadian securities regulators, the listing requirements of the Exchange and other applicable securities rules and regulations. Compliance with these rules and regulations may increase the Company's legal and financial compliance costs, may make some activities more difficult, time-consuming or costly and may increase the demand on the Company's systems and resources. Being a public

company requires that the Company file continuous disclosure documents, including, among other things, annual and quarterly financial statements. Management's attention may be diverted from other business concerns, which could have a material adverse effect on the Company's business, financial condition and results of operations. The Company may need to hire more employees in the future, which will increase its costs and expenses.

In addition, changing laws, regulations and standards relating to corporate governance and public disclosure create uncertainty for public companies, increasing legal and financial compliance costs and making some activities more time consuming. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. The Company may invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management's time and attention from revenue-generating activities to compliance activities. If the Company's efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory authorities, legal proceedings may be initiated against the Company and its business may be harmed.

***Trading in the Company's common shares outside of Canada may be subject to restrictions on trading under foreign securities laws, and purchasers of securities under private placements by the Company will be subject to certain restrictions on trading***

The Company's common shares trade on the TSX and are freely tradeable only in Canada. As such, shareholders trading the Company's common shares outside of Canada may be subject to restrictions imposed by foreign securities laws that may restrict their ability to transfer shares freely or at all. Certain securities offered by the Company pursuant to its private placements, including the unlisted warrants issued by the Company, are subject to certain initial hold periods and other restrictions on trading imposed by applicable securities laws and, in the case of the warrants, pursuant to the terms of the applicable warrant certificates. These restrictions may affect the liquidity of the investment of certain shareholders in the securities of the Company.

***General economic conditions may have an adverse effect on the Company and its business***

Continuing global economic volatility and uncertainty may have an adverse effect on the Company and its business, including without limitation the ability to raise additional financing, to obtain strategic partner support or commercialization opportunities and alliances for the Company's new drug candidates, and to obtain continued services and supplies.

***The Company's business involves environmental risks that could result in accidental contamination, injury, and significant capital expenditures in order to comply with environmental laws and regulations***

The Company and its commercial collaborators are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of materials and certain waste products. Although the Company believes that its safety procedures comply with the regulations, the risk of accidental contamination or injury from these materials cannot be eliminated. In the event of such an accident, the Company could be held liable for any damages that result and any such liability could exceed the resources of the Company. The Company is not specifically insured with respect to this liability. The Company (or its collaborators) may be required to incur significant costs to comply with environmental laws and regulations in the future; and the operations, business or assets of the Company may be materially adversely affected by current or future environmental laws or regulations.

***Any failure to maintain an effective system of internal controls may result in material misstatements of our consolidated financial statements or cause us to fail to meet our reporting obligations or fail to prevent fraud; and in that case, our shareholders could lose confidence in our financial reporting, which would harm our business, could negatively impact the price of our common shares and prevent the Company from raising additional capital.***

Effective internal controls are necessary for the Company to provide reliable financial reports and prevent fraud. If the Company fails to maintain an effective system of internal controls, the Company may not be able to report its financial results accurately or prevent fraud; and in that case, the Company's shareholders could lose confidence in our financial reporting, which would harm our business, negatively impact the price of the Company's common shares and also prevent the Company from raising additional capital. Even if we were to conclude that our internal control over financial reporting provides reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with IFRS as issued by the IASB, because of its inherent limitations, internal control over financial reporting may not prevent or detect fraud or misstatements. Failure to achieve and maintain effective internal control over financial reporting could prevent the Company from complying with its reporting obligations on a timely basis, which could result in the loss of investor confidence in the reliability of the Company's consolidated financial statements, harm our business, negatively impact the trading price of our common shares and prevent the Company from raising additional capital.

### **Novel Coronavirus (“COVID-19”)**

The World Health Organization has declared COVID-19 a pandemic. The Company is actively assessing and responding where possible to the potential impact of the COVID-19 pandemic. The risk to the Company, the health of its employees and to those third-party vendors that support the Company and its operations is high. Any impact on the Company arising from the pandemic could have a material adverse effect on the Company’s business, results of operations and financial condition.

### **RISK FACTORS IN OTHER PUBLIC FILINGS**

For all of the reasons set forth above, together with those additional risk factors identified under the headings “*Forward-Looking Statements*” and “*Risk Factors*” in the Company’s most recent Annual Information Form filed under the Company’s profile on SEDAR at [www.sedar.com](http://www.sedar.com), investors should not place undue reliance on forward-looking information. Other than any obligation to disclose material information under applicable securities laws, the Company undertakes no obligation to revise or update any forward-looking information after the date hereof.

Data relevant to estimated market sizes and penetration for the Company’s lead products under development are presented in this MD&A. This data has been obtained from a variety of published resources including published scientific literature, websites and information generally available through publicized means. The Company attempts to source reference data from multiple sources whenever possible for confirmatory purposes. Although the Company believes the foregoing data is reliable, the Company has not independently verified the accuracy and completeness of this data.

### **ADDITIONAL INFORMATION**

Additional information relating to the Company’s fiscal year ended July 31, 2019, is available under the Company’s profile on SEDAR at [www.sedar.com](http://www.sedar.com).

July 29, 2020

---